```
* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1          Web Page for STN Seminar Schedule - N. America
 NEWS  2  OCT 02  CA/CAplus enhanced with pre-1907 records from Chemisches
                  Zentralblatt
 NEWS  3  OCT 19  BEILSTEIN updated with new compounds
 NEWS  4  NOV 15  Derwent Indian patent publication number format enhanced
 NEWS  5  NOV 19  WPIX enhanced with XML display format
 NEWS  6  NOV 30  ICSD reloaded with enhancements
 NEWS  7  DEC 04  LINPADOCDB now available on STN
 NEWS  8  DEC 14  BEILSTEIN pricing structure to change
 NEWS  9  DEC 17  USPATOLD added to additional database clusters
 NEWS 10  DEC 17  IMSDRUGCONF removed from database clusters and STN
 NEWS 11  DEC 17  DGENE now includes more than 10 million sequences
 NEWS 12  DEC 17  TOXCENTER enhanced with 2008 MeSH vocabulary in
                  MEDLINE segment
 NEWS 13  DEC 17  MEDLINE and LMEDLINE updated with 2008 MeSH vocabulary
 NEWS 14  DEC 17  CA/CAplus enhanced with new custom IPC display formats
 NEWS 15  DEC 17  STN Viewer enhanced with full-text patent content
                  from USPATOLD
 NEWS 16  JAN 02  STN pricing information for 2008 now available
 NEWS 17  JAN 16  CAS patent coverage enhanced to include exemplified
                  prophetic substances
 NEWS 18  JAN 28  USPATFULL, USPAT2, and USPATOLD enhanced with new
                  custom IPC display formats
 NEWS 19  JAN 28  MARPAT searching enhanced
 NEWS 20  JAN 28  USGENE now provides USPTO sequence data within 3 days
                  of publication
 NEWS 21  JAN 28  TOXCENTER enhanced with reloaded MEDLINE segment
 NEWS 22  JAN 28  MEDLINE and LMEDLINE reloaded with enhancements
 NEWS 23  FEB 08  STN Express, Version 8.3, now available
 NEWS 24  FEB 20  PCI now available as a replacement to DPCI
 NEWS 25  FEB 25  IFIREF reloaded with enhancements
 NEWS 26  FEB 25  IMSPRODUCT reloaded with enhancements
 NEWS 27  FEB 29  WPINDEX/WPIDS/WPIX enhanced with ECLA and current
                  U.S. National Patent Classification


 NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,
              AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 18:52:25 ON 02 MAR 2008

=> file uspatall
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.21       0.21

FILE 'USPATFULL' ENTERED AT 18:52:52 ON 02 MAR 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)
```

```
FILE 'USPATOLD' ENTERED AT 18:52:52 ON 02 MAR 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 18:52:52 ON 02 MAR 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

=> s (multi-layer?)
L1      140563 (MULTI-LAYER?)

=> s (ppi layer or proton pump inhibit? layer)
L2           2 (PPI LAYER OR PROTON PUMP INHIBIT? LAYER)

=> d 1-2

L2   ANSWER 1 OF 2  USPATFULL on STN
Full Text
AN      2004:215056  USPATFULL
TI      Novel pharmaceutical formulation containing a proton pump inhibitor and
        an antacid
IN      Niecestro, Robert, Pocono Pines, PA, UNITED STATES
        Kositprapa, Unchalee, Davie, FL, UNITED STATES
        Oh, Yoon, Pembroke Pines, FL, UNITED STATES
        Nangia, Avinash, Weston, FL, UNITED STATES
        Cardinal, John R., Tamarac, FL, UNITED STATES
        Hahn, Elliot F., North Miami Beach, FL, UNITED STATES
PI      US 2004166162        A1  20040826
AI      US 2004-761805       A1  20040121 (10)
PRAI    US 2003-442337P      20030124 (60)
DT      Utility
FS      APPLICATION
LN.CNT 1055
INCL    INCLM: 424/472.000
        INCLS: 514/339.000
NCL     NCLM:  424/472.000
        NCLS:  514/339.000
IC      [7]
        ICM    A61K031-4439
        ICS    A61K009-24
        IPCI   A61K0031-4439 [ICM,7]; A61K0031-4427 [ICM,7,C*]; A61K0009-24
               [ICS,7]
        IPCR   A61K0009-24 [I,C*]; A61K0009-24 [I,A]; A61K0031-4427 [I,C*];
               A61K0031-4439 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2   ANSWER 2 OF 2  USPATFULL on STN
Full Text
AN      2004:7871  USPATFULL
TI      Transmucosal delivery of proton pump inhibitors
IN      Widder, Kenneth, Rancho Santa Fe, CA, UNITED STATES
        Hall, Warren, San Diego, CA, UNITED STATES
        Olmstead, Kay, San Diego, CA, UNITED STATES
PI      US 2004006111        A1  20040108
AI      US 2003-353143       A1  20030127 (10)
PRAI    US 2002-351909P      20020125 (60)
        US 2002-374761P      20020422 (60)
DT      Utility
FS      APPLICATION
LN.CNT 1161
INCL    INCLM: 514/338.000
        INCLS: 424/471.000
NCL     NCLM:  514/338.000
        NCLS:  424/471.000
IC      [7]
        ICM    A61K031-4439
        ICS    A61K009-24
        IPCI   A61K0031-4439 [ICM,7]; A61K0031-4427 [ICM,7,C*]; A61K0009-24
               [ICS,7]
        IPCR   A61K0009-00 [I,C*]; A61K0009-00 [I,A]; A61K0009-24 [I,C*];
               A61K0009-24 [I,A]; A61K0031-4427 [I,C*]; A61K0031-4439 [I,A];
               A61K0033-06 [I,C*]; A61K0033-10 [I,A]; A61K0045-00 [I,C*];
               A61K0045-06 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
```

```
=> (proton pump inhibit? gran/)
(PROTON IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> (proton pump inhibit? gran?)
(PROTON IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s (proton pump inhibit? gran?)
L3            4 (PROTON PUMP INHIBIT? GRAN?)

=> d 1-4

L3   ANSWER 1 OF 4  USPATFULL on STN
Full Text
AN      2007:277813  USPATFULL
TI      Oral dosage forms including an antiplatelet agent and an acid inhibitor
IN      Goldsmith, Mark A., Menlo Park, CA, UNITED STATES
        Vadas, Elizabeth, Dorval, CANADA
PA      Cogentus Pharmaceuticals, Inc, Menlo Park, CA, UNITED STATES (U.S.
        corporation)
PI      US 2007243243        A1  20071018
AI      US 2007-696554       A1  20070404 (11)
PRAI    US 2006-789543P      20060404 (60)
        US 2006-812326P      20060609 (60)
DT      Utility
FS      APPLICATION
LN.CNT 3072
INCL    INCLM: 424/451.000
        INCLS: 514/165.000; 514/301.000; 514/338.000; 424/464.000
NCL     NCLM:  424/451.000
        NCLS:  424/464.000; 514/165.000; 514/301.000; 514/338.000
IC      IPCI   A61K0031-616 [I,A]; A61K0031-60 [I,C*]; A61K0031-4743 [I,A];
               A61K0031-4738 [I,C*]; A61K0031-4439 [I,A]; A61K0031-4427 [I,C*];
               A61K0009-48 [I,A]; A61K0009-20 [I,A]
        IPCR   A61K0031-60 [I,C]; A61K0031-616 [I,A]; A61K0009-20 [I,C];
               A61K0009-20 [I,A]; A61K0009-48 [I,C]; A61K0009-48 [I,A];
               A61K0031-4427 [I,C]; A61K0031-4439 [I,A]; A61K0031-4738 [I,C];
               A61K0031-4743 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3   ANSWER 2 OF 4  USPATFULL on STN
Full Text
AN      2007:176725  USPATFULL
TI      Oral pharmaceutical formulations containing non-steroidal
        anti-inflammatory drugs and acid inhibitors
IN      Tananbaum, James B., Palo Alto, CA, UNITED STATES
        Vadas, Elizabeth, Dorval, CANADA
        Goldsmith, Mark A., Menlo Park, CA, UNITED STATES
PA      Cogentus Pharmaceuticals, Inc., Menlo Park, CA, UNITED STATES (U.S.
        corporation)
PI      US 2007154542        A1  20070705
AI      US 2006-640107       A1  20061215 (11)
PRAI    US 2005-755131P      20051230 (60)
DT      Utility
FS      APPLICATION
LN.CNT 832
INCL    INCLM: 424/457.000
        INCLS: 514/226.200
NCL     NCLM:  424/457.000
        NCLS:  514/226.200
IC      IPCI   A61K0031-5415 [I,A]; A61K0009-52 [I,A]
        IPCR   A61K0031-5415 [I,C]; A61K0031-5415 [I,A]; A61K0009-52 [I,C];
               A61K0009-52 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
```

```
L3   ANSWER 3 OF 4  USPATFULL on STN
Full Text
AN      2006:240140  USPATFULL
TI      Pharmaceutical formulations useful for inhibiting acid secretion and
        methods for making and using them
IN      Hall, Warren, Del Mar, CA, UNITED STATES
        Olmstead, Kay, San Diego, CA, UNITED STATES
        Weston, Laura, Escondido, CA, UNITED STATES
PA      Santarus, Inc. (U.S. corporation)
PI      US 2006204585       A1  20060914
AI      US 2006-338608      A1  20060124 (11)
RLI     Continuation-in-part of Ser. No. US 2004-893203, filed on 16 Jul 2004,
        PENDING
PRAI    US 2003-488321P     20030718 (60)
DT      Utility
FS      APPLICATION
LN.CNT 4308
INCL    INCLM: 424/489.000
        INCLS: 514/338.000; 424/717.000; 424/715.000
NCL     NCLM:  424/489.000
        NCLS:  424/715.000; 424/717.000; 514/338.000
IC      IPCI   A61K0031-4439 [I,A]; A61K0031-4427 [I,C*]; A61K0009-14 [I,A];
               A61K0033-00 [I,A]
        IPCR   A61K0031-4427 [I,C]; A61K0031-4439 [I,A]; A61K0009-14 [I,C];
               A61K0009-14 [I,A]; A61K0009-20 [I,C*]; A61K0009-20 [I,A];
               A61K0009-46 [I,C*]; A61K0009-46 [I,A]; A61K0033-00 [I,C];
               A61K0033-00 [I,A]; A61K0033-06 [I,C*]; A61K0033-06 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3   ANSWER 4 OF 4  USPATFULL on STN
Full Text
AN      2004:215056  USPATFULL
TI      Novel pharmaceutical formulation containing a proton pump inhibitor and
        an antacid
IN      Niecestro, Robert, Pocono Pines, PA, UNITED STATES
        Kositprapa, Unchalee, Davie, FL, UNITED STATES
        Oh, Yoon, Pembroke Pines, FL, UNITED STATES
        Nangia, Avinash, Weston, FL, UNITED STATES
        Cardinal, John R., Tamarac, FL, UNITED STATES
        Hahn, Elliot F., North Miami Beach, FL, UNITED STATES
PI      US 2004166162       A1  20040826
AI      US 2004-761805      A1  20040121 (10)
PRAI    US 2003-442337P     20030124 (60)
DT      Utility
FS      APPLICATION
LN.CNT 1055
INCL    INCLM: 424/472.000
        INCLS: 514/339.000
NCL     NCLM:  424/472.000
        NCLS:  514/339.000
IC      [7]
        ICM    A61K031-4439
        ICS    A61K009-24
        IPCI   A61K0031-4439 [ICM,7]; A61K0031-4427 [ICM,7,C*]; A61K0009-24
               [ICS,7]
        IPCR   A61K0009-24 [I,C*]; A61K0009-24 [I,A]; A61K0031-4427 [I,C*];
               A61K0031-4439 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.


=> s (omperazole or lansoprazole or pantoprazole or pariprazole or leminoprazole)
L4         1960 (OMPERAZOLE OR LANSOPRAZOLE OR PANTOPRAZOLE OR PARIPRAZOLE OR
                LEMINOPRAZOLE)

=> s (proton pump inhibit?)
L5         2032 (PROTON PUMP INHIBIT?)

=> s l4 or l5
L6         2992 L4 OR L5

=> s (layer? and gran?)
L7       272277 (LAYER? AND GRAN?)
```

```
=> s l6 and l7
L8          1474 L6 AND L7

=> s (antacid layer?)
L9             6 (ANTACID LAYER?)

=> s l8 and l9
L10            2 L8 AND L9

=> d l-2

L10  ANSWER 1 OF 2  USPATFULL on STN
Full Text
AN      2005:323970  USPATFULL
TI      Solid dosage form for acid-labile active ingredient
IN      Li, Shun-Por, Lansdale, PA, UNITED STATES
        Wynn, David, Huntingdon Valley, PA, UNITED STATES
        Sowden, Harry S., Glenside, PA, UNITED STATES
PI      US 2005281876        A1  20051222
AI      US 2004-871851       A1  20040618 (10)
DT      Utility
FS      APPLICATION
LN.CNT 1501
INCL    INCLM: 424/473.000
NCL     NCLM:  424/473.000
IC      [7]
        ICM    A61K009-24
        ICS    A61K009-36
        IPCI   A61K0009-24 [ICM,7]; A61K0009-36 [ICS,7]; A61K0009-30 [ICS,7,C*]
        IPCR   A61K0009-14 [I,C*]; A61K0009-14 [I,A]; A61K0009-20 [I,C*];
               A61K0009-20 [I,A]; A61K0009-24 [I,C*]; A61K0009-24 [I,A];
               A61K0009-28 [I,C*]; A61K0009-28 [I,A]; A61K0009-30 [I,C*];
               A61K0009-36 [I,A]; A61M0031-00 [I,C*]; A61M0031-00 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10  ANSWER 2 OF 2  USPATFULL on STN
Full Text
AN      2004:215056  USPATFULL
TI      Novel pharmaceutical formulation containing a proton pump
        inhibitor and an antacid
IN      Niecestro, Robert, Pocono Pines, PA, UNITED STATES
        Kositprapa, Unchalee, Davie, FL, UNITED STATES
        Oh, Yoon, Pembroke Pines, FL, UNITED STATES
        Nangia, Avinash, Weston, FL, UNITED STATES
        Cardinal, John R., Tamarac, FL, UNITED STATES
        Hahn, Elliot F., North Miami Beach, FL, UNITED STATES
PI      US 2004166162        A1  20040826
AI      US 2004-761805       A1  20040121 (10)
PRAI    US 2003-442337P      20030124 (60)
DT      Utility
FS      APPLICATION
LN.CNT 1055
INCL    INCLM: 424/472.000
        INCLS: 514/339.000
NCL     NCLM:  424/472.000
        NCLS:  514/339.000
IC      [7]
        ICM    A61K031-4439
        ICS    A61K009-24
        IPCI   A61K0031-4439 [ICM,7]; A61K0031-4427 [ICM,7,C*]; A61K0009-24
               [ICS,7]
        IPCR   A61K0009-24 [I,C*]; A61K0009-24 [I,A]; A61K0031-4427 [I,C*];
               A61K0031-4439 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.


=> d his

     (FILE 'HOME' ENTERED AT 18:52:25 ON 02 MAR 2008)

     FILE 'USPATFULL, USPATOLD, USPAT2' ENTERED AT 18:52:52 ON 02 MAR 2008
```

```
L1       140563 S (MULTI-LAYER?)
L2            2 S (PPI LAYER OR PROTON PUMP INHIBIT? LAYER)
L3            4 S (PROTON PUMP INHIBIT? GRAN?)
L4         1960 S (OMPERAZOLE OR LANSOPRAZOLE OR PANTOPRAZOLE OR PARIPRAZOLE OR
L5         2032 S (PROTON PUMP INHIBIT?)
L6         2992 S L4 OR L5
L7       272277 S (LAYER? AND GRAN?)
L8         1474 S L6 AND L7
L9            6 S (ANTACID LAYER?)
L10           2 S L8 AND L9

=> s (omperazole or lansoprazole or pantoprazole or pariprazole or leminoprazole)/clm
L11         499 (OMPERAZOLE OR LANSOPRAZOLE OR PANTOPRAZOLE OR PARIPRAZOLE OR
                LEMINOPRAZOLE)/CLM

=> s (proton pump inhibit?)/clm
L12         484 (PROTON PUMP INHIBIT?)/CLM

=> s l11 or l12
L13         737 L11 OR L12

=> s (layer? and gran?)/clm
L14       10742 (LAYER? AND GRAN?)/CLM

=> s l13 and l14
L15          58 L13 AND L14

=> d 1-58

L15  ANSWER 1 OF 58  USPATFULL on STN
Full Text
AN     2008:22877  USPATFULL
TI     Solid Dosage Form Comprising Proton Pump Inhibitor and Suspension Made
       Thereof
IN     Persson, Eva, Lund, SWEDEN
       Trofast, Eva, Lund, SWEDEN
PA     ASTRAZENECA AB, Sodertalje, SWEDEN, SE-151 85 (non-U.S. corporation)
PI     US 2008020053       A1  20080124
AI     US 2005-722387      A1  20051220 (11)
       WO 2005-SE1972          20051220
                               20070621  PCT 371 date
PRAI   US 2004-638435P     20041222 (60)
DT     Utility
FS     APPLICATION
LN.CNT 1033
INCL   INCLM: 424/490.000
       INCLS: 514/303.000; 514/338.000; 514/777.000
NCL    NCLM:  424/490.000
       NCLS:  514/303.000; 514/338.000; 514/777.000
IC     IPCI   A61K0031-4439 [I,A]; A61K0031-444 [I,A]; A61K0031-4427 [I,C*];
              A61K0047-36 [I,A]; A61K0009-14 [I,A]; A61P0043-00 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15  ANSWER 2 OF 58  USPATFULL on STN
Full Text
AN     2007:224389  USPATFULL
TI     Stable oral formulation containing benzimidazole derivative
IN     Vanderbist, Francis, Beersel, BELGIUM
       Sereno, Antonio, Melsbroek, BELGIUM
       Baudier, Philippe, Uccle, BELGIUM
       Deboeck, Arthur, Gurabo, PR, UNITED STATES
PI     US 2007196486       A1  20070823
AI     US 2007-790054      A1  20070423 (11)
RLI    Continuation of Ser. No. US 2003-399482, filed on 18 Apr 2003, ABANDONED
PRAI   WO 2000-BE126       20001020
       WO 2001-BE184       20011018
DT     Utility
FS     APPLICATION
LN.CNT 585
INCL   INCLM: 424/472.000
       INCLS: 514/338.000
NCL    NCLM:  424/472.000
```

```
       NCLS:  514/338.000
IC     IPCI   A61K0009-24 [I,A]; A61K0031-4439 [I,A]; A61K0031-4427 [I,C*]
       IPCR   A61K0009-24 [I,C]; A61K0009-24 [I,A]; A61K0031-4427 [I,C];
              A61K0031-4439 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15  ANSWER 3 OF 58  USPATFULL on STN
Full Text
AN     2007:217184  USPATFULL
TI     Delayed release pharmaceutical oral dosage form and method of making
       same
IN     Zerbe, Horst G., Hudson, CANADA
       Ispas-Szabo, Pompilia, Greenfield Park, CANADA
PA     Intelgenx Corp., Saint-Laurent, CANADA (non-U.S. corporation)
PI     US 2007190139        A1  20070816
AI     US 2006-403262       A1  20060413 (11)
PRAI   US 2006-772547P      20060213 (60)
DT     Utility
FS     APPLICATION
LN.CNT 1491
INCL   INCLM: 424/468.000
       INCLS: 514/573.000
NCL    NCLM:  424/468.000
       NCLS:  514/573.000
IC     IPCI   A61K0009-22 [I,A]; A61K0031-557 [I,A]
       IPCR   A61K0009-22 [I,C]; A61K0009-22 [I,A]; A61K0031-557 [I,C];
              A61K0031-557 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15  ANSWER 4 OF 58  USPATFULL on STN
Full Text
AN     2007:191199  USPATFULL
TI     Taste masked compositions of erythromycin a and derivatives thereof
IN     Dabre, Rahul, Nagpur, INDIA
       Nagaprasad, Vishnubhotla, Hyderabad, INDIA
       Malik, Rajiv, Vienna, AUSTRIA
PI     US 2007167380        A1  20070719
AI     US 2003-509824       A1  20030403 (10)
       WO 2003-IB1221           20030403
                                20050622  PCT 371 date
PRAI   IN 2002-4262002      20020403
DT     Utility
FS     APPLICATION
LN.CNT 435
INCL   INCLM: 514/029.000
       INCLS: 514/054.000
NCL    NCLM:  514/029.000
       NCLS:  514/054.000
IC     IPCI   A61K0031-7048 [I,A]; A61K0031-7042 [I,C*]; A61K0031-734 [I,A]
       IPCR   A61K0031-7042 [I,C]; A61K0031-7048 [I,A]; A61K0009-16 [I,C*];
              A61K0009-16 [I,A]; A61K0009-50 [I,C*]; A61K0009-50 [I,A];
              A61K0031-429 [I,C*]; A61K0031-43 [I,A]; A61K0031-4427 [I,C*];
              A61K0031-4439 [I,A]; A61K0031-734 [I,C]; A61K0031-734 [I,A];
              A61K0038-55 [I,C*]; A61K0038-55 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15  ANSWER 5 OF 58  USPATFULL on STN
Full Text
AN     2007:190191  USPATFULL
TI     Proton pump-inhibitor-containing capsules which comprise subunits
       differently structured for a delayed release of the active ingredient
IN     Odidi, Isa, Toronto, CANADA
       Odidi, Amina, Toronto, CANADA
PI     US 2007166370        A1  20070719
AI     US 2004-561700       A1  20040603 (10)
       WO 2004-CA825            20040603
                                20061110  PCT 371 date
PRAI   US 2003-482439P      20030626 (60)
       US 2004-548903P      20040302 (60)
DT     Utility
FS     APPLICATION
LN.CNT 1285
```

INCL INCLM: 424/451.000
INCLS: 424/457.000; 514/338.000
NCL NCLM: 424/451.000
NCLS: 424/457.000; 514/338.000
IC IPCI A61K0009-48 [I,A]; A61K0009-52 [I,A]; A61K0031-4439 [I,A]; A61K0031-4427 [I,C*]
IPCR A61K0009-48 [I,C]; A61K0009-48 [I,A]; A61K0009-16 [N,C*]; A61K0009-16 [N,A]; A61K0009-20 [I,C*]; A61K0009-20 [I,A]; A61K0009-28 [I,C*]; A61K0009-28 [I,A]; A61K0009-50 [I,C*]; A61K0009-50 [I,A]; A61K0009-52 [I,C]; A61K0009-52 [I,A]; A61K0031-00 [I,C*]; A61K0031-00 [I,A]; A61K0031-44 [I,C*]; A61K0031-44 [I,A]; A61K0031-4427 [I,C]; A61K0031-4439 [I,A]; A61K0045-00 [I,C*]; A61K0045-06 [I,A]; A61P0001-00 [I,C*]; A61P0001-04 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 6 OF 58 USPATFULL on STN
Full Text
AN 2007:161584 USPATFULL
TI Stable capsule preparation
IN Nagahara, Naoki, Osaka-shi, JAPAN
Ito, Hiroki, Suita-shi, JAPAN
Nonomura, Muneo, Osaka-shi, JAPAN
PI US 2007141137 A1 20070621
AI US 2005-591164 A1 20050303 (10)
WO 2005-JP3621 20050303
20060830 PCT 371 date
PRAI JP 2004-60613 20040304
DT Utility
FS APPLICATION
LN.CNT 1890
INCL INCLM: 424/451.000
INCLS: 514/338.000
NCL NCLM: 424/451.000
NCLS: 514/338.000
IC IPCI A61K0031-4439 [I,A]; A61K0031-4427 [I,C*]; A61K0009-48 [I,A]
IPCR A61K0031-4427 [I,C]; A61K0031-4439 [I,A]; A61K0009-48 [I,C]; A61K0009-48 [I,A]; A61K0009-52 [I,C*]; A61K0009-58 [I,A]; A61K0045-00 [I,C*]; A61K0045-00 [I,A]; A61K0047-34 [I,C*]; A61K0047-34 [I,A]; A61K0047-42 [I,C*]; A61K0047-42 [I,A]; A61P0001-00 [I,C*]; A61P0001-04 [I,A]; C07D0401-00 [N,C*]; C07D0401-12 [N,A]; A61K0047-36 [I,C*]; A61K0047-36 [I,A]; A61K0047-42 [I,C*]; A61K0047-42 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 7 OF 58 USPATFULL on STN
Full Text
AN 2007:55439 USPATFULL
TI Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof
IN Heese, Gerd-Ulfert, Munich, GERMANY, FEDERAL REPUBLIC OF
Junger, Herbert, Dachau, GERMANY, FEDERAL REPUBLIC OF
Laicher, Arnim, Sauerlach, GERMANY, FEDERAL REPUBLIC OF
Lorck, Claudio, Munich, GERMANY, FEDERAL REPUBLIC OF
Profitlich, Thomas, Munich, GERMANY, FEDERAL REPUBLIC OF
Weiss, Gerd, Munich, GERMANY, FEDERAL REPUBLIC OF
PI US 2007048380 A1 20070301
US 7276253 B2 20071002
AI US 2006-502830 A1 20060811 (11)
RLI Division of Ser. No. US 2003-665081, filed on 16 Sep 2003, ABANDONED Continuation of Ser. No. US 2001-947166, filed on 5 Sep 2001, GRANTED, Pat. No. US 6623759 Continuation of Ser. No. US 1998-219985, filed on 23 Dec 1998, ABANDONED Continuation of Ser. No. WO 1997-EP3387, filed on 27 Jun 1997, UNKNOWN
PRAI DE 1996-19626045 19960628
DT Utility
FS APPLICATION
LN.CNT 967
INCL INCLM: 424/472.000
INCLS: 514/338.000
NCL NCLM: 424/472.000
NCLS: 424/464.000; 424/471.000; 424/474.000; 424/480.000; 424/489.000;

```
                424/490.000; 424/494.000; 514/338.000
IC      IPCI    A61K0009-24 [I,A]; A61K0031-4439 [I,A]; A61K0031-4427 [I,C*]
        IPCI-2  A61K0009-14 [I,A]; A61K0009-16 [I,A]; A61K0009-20 [I,A];
                A61K0009-24 [I,A]; A61K0009-28 [I,A]
        IPCR    A61K0009-14 [I,C]; A61K0009-14 [I,A]; A61K0009-16 [I,C];
                A61K0009-16 [I,A]; A61K0009-20 [I,C]; A61K0009-20 [I,A];
                A61K0009-24 [I,C]; A61K0009-24 [I,A]; A61K0009-28 [I,C];
                A61K0009-28 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15  ANSWER 8 OF 58  USPATFULL on STN
Full Text
AN      2007:48221  USPATFULL
TI      Pellet formulations of acid-labile benzimidazonle compounds
IN      Martin, Luis Carvajal, Madrid, SPAIN
        Asensio, Juan Carlos Asensio, Zaragoza, SPAIN
        Tirado, Francisco Javier Sevilla, Zaragoza, SPAIN
PI      US 2007042043         A1  20070222
AI      US 2004-554727        A1  20040427 (10)
        WO 2004-EP50618           20040427
                                  20051028  PCT 371 date
PRAI    ES 2003-976           20030429
DT      Utility
FS      APPLICATION
LN.CNT 515
INCL    INCLM: 424/470.000
        INCLS: 514/338.000; 424/489.000
NCL     NCLM:  424/470.000
        NCLS:  424/489.000; 514/338.000
IC      IPCI   A61K0031-4439 [I,A]; A61K0031-4427 [I,C*]; A61K0009-26 [I,A];
               A61K0009-14 [I,A]
        IPCR   A61K0031-4427 [I,C]; A61K0031-4439 [I,A]; A61K0009-14 [I,C];
               A61K0009-14 [I,A]; A61K0009-26 [I,C]; A61K0009-26 [I,A];
               A61K0009-50 [I,C*]; A61K0009-50 [I,A]; A61P0001-00 [I,C*];
               A61P0001-04 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15  ANSWER 9 OF 58  USPATFULL on STN
Full Text
AN      2007:35958  USPATFULL
TI      Gastric acid secretion inhibiting composition
IN      Pettersson, Anders, Lilla Edet, SWEDEN
        Nystrom, Christer, Uppsala, SWEDEN
        Hakansson, Yvonne, Uppsala, SWEDEN
PA      OREXO AB, UPPSALA, SWEDEN (non-U.S. corporation)
PI      US 2007031497         A1  20070208
AI      US 2006-544750        A1  20061010 (11)
RLI     Continuation of Ser. No. US 2005-531598, filed on 25 Nov 2005, PENDING A
        371 of International Ser. No. WO 2003-SE1598, filed on 15 Oct 2003
PRAI    SE 2002-3065          20021016
DT      Utility
FS      APPLICATION
LN.CNT 1345
INCL    INCLM: 424/473.000
        INCLS: 514/338.000
NCL     NCLM:  424/473.000
        NCLS:  514/338.000
IC      IPCI   A61K0031-4439 [I,A]; A61K0031-4427 [I,C*]; A61K0009-24 [I,A]
        IPCR   A61K0031-4427 [I,C]; A61K0031-4439 [I,A]; A61K0009-00 [I,C*];
               A61K0009-00 [I,A]; A61K0009-16 [N,C*]; A61K0009-16 [N,A];
               A61K0009-20 [I,C*]; A61K0009-20 [I,A]; A61K0009-24 [I,C];
               A61K0009-24 [I,A]; A61K0009-48 [I,C*]; A61K0009-48 [I,A];
               A61K0009-50 [I,C*]; A61K0009-50 [I,A]; A61K0031-341 [I,C*];
               A61K0031-341 [I,A]; A61K0031-4164 [I,C*]; A61K0031-4164 [I,A];
               A61K0031-426 [I,C*]; A61K0031-426 [I,A]; A61K0045-00 [I,C*];
               A61K0045-06 [I,A]; A61P0001-00 [I,C*]; A61P0001-04 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15  ANSWER 10 OF 58  USPATFULL on STN
Full Text
AN      2006:301112  USPATFULL
TI      Compositions and methods for inhibiting gastric acid secretion
```

```
IN      Kostadinov, Aleksey, Rehovot, ISRAEL
        David, Ayelet, Negev, ISRAEL
        Glozman, Sabina, Rehovot, ISRAEL
PI      US 2006257467       A1  20061116
AI      US 2005-191688      A1  20050727 (11)
PRAI    US 2005-679664P     20050511 (60)
DT      Utility
FS      APPLICATION
LN.CNT 983
INCL    INCLM: 424/451.000
        INCLS: 514/338.000; 514/557.000; 514/574.000; 424/464.000; 424/466.000;
               424/468.000
NCL     NCLM:  424/451.000
        NCLS:  424/464.000; 424/466.000; 424/468.000; 514/338.000; 514/557.000;
               514/574.000
IC      IPCI   A61K0031-4439 [I,A]; A61K0031-4427 [I,C*]; A61K0031-19 [I,A];
               A61K0031-185 [I,C*]; A61K0009-48 [I,A]; A61K0009-20 [I,A];
               A61K0009-46 [I,A]; A61K0009-22 [I,A]
        IPCR   A61K0031-4427 [I,C]; A61K0031-4439 [I,A]; A61K0009-20 [I,C];
               A61K0009-20 [I,A]; A61K0009-22 [I,C]; A61K0009-22 [I,A];
               A61K0009-46 [I,C]; A61K0009-46 [I,A]; A61K0009-48 [I,C];
               A61K0009-48 [I,A]; A61K0031-185 [I,C]; A61K0031-19 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15  ANSWER 11 OF 58  USPATFULL on STN
Full Text
AN      2006:195039  USPATFULL
TI      Spheroids, preparation method thereof and pharmaceutical compositions
IN      Chenevier, Philippe, 5656 rue Woudbury, Montreal, QC, CANADA  H3T 1F7
        Marechal, Dominique, Laval, CANADA
PA      Ethypharm, Houdan, FRANCE, F-78550 (non-U.S. corporation)
PI      US 2006165794       A1  20060727
AI      US 2003-530052      A1  20031003 (10)
        WO 2003-FR2909          20031003
                                20050804  PCT 371 date
PRAI    FR 2002-12333       20021004
DT      Utility
FS      APPLICATION
LN.CNT 744
INCL    INCLM: 424/472.000
NCL     NCLM:  424/472.000
IC      IPCI   A61K0009-24 [I,A]
        IPCR   A61K0009-24 [I,A]; A61K0009-20 [I,C*]; A61K0009-20 [I,A];
               A61K0009-22 [I,C*]; A61K0009-22 [I,A]; A61K0009-24 [I,C];
               A61K0009-50 [I,C*]; A61K0009-50 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15  ANSWER 12 OF 58  USPATFULL on STN
Full Text
AN      2006:188327  USPATFULL
TI      Stable pharmaceutical composition comprising an active substance in the
        form of solid solution
IN      Stanic Ljubin, Tijana, Ljubljana, SLOVENIA
        Sirca, Judita, Ljubljana, SLOVENIA
PI      US 2006159762       A1  20060720
AI      US 2005-317769      A1  20051223 (11)
PRAI    SI 2004-200400351   20041224
DT      Utility
FS      APPLICATION
LN.CNT 768
INCL    INCLM: 424/472.000
        INCLS: 514/338.000
NCL     NCLM:  424/472.000
        NCLS:  514/338.000
IC      IPCI   A61K0031-4439 [I,A]; A61K0031-4427 [I,C*]; A61K0009-24 [I,A]
        IPCR   A61K0031-4427 [I,C]; A61K0031-4439 [I,A]; A61K0009-24 [I,C];
               A61K0009-24 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15  ANSWER 13 OF 58  USPATFULL on STN
Full Text
AN      2006:188325  USPATFULL
```

```
TI     Drug composition having active ingredient adhered at high concentration
       to spherical core
IN     Yoneyama, Shuji, Osaka-shi, JAPAN
       Bando, Hiroto, Osaka-shi, JAPAN
PA     Aoyama & Partners (non-U.S. corporation)
PI     US 2006159760        A1  20060720
AI     US 2004-548504       A1  20040310 (10)
       WO 2004-JP3075           20040310
                                20050909  PCT 371 date
PRAI   JP 2003-66344        20030312
DT     Utility
FS     APPLICATION
LN.CNT 6689
INCL   INCLM: 424/472.000
       INCLS: 514/338.000
NCL    NCLM:  424/472.000
       NCLS:  514/338.000
IC     IPCI   A61K0031-4439 [I,A]; A61K0031-4427 [I,C*]; A61K0009-24 [I,A]
       IPCR   A61K0031-4427 [I,C]; A61K0031-4439 [I,A]; A61K0009-16 [I,C*];
              A61K0009-16 [I,A]; A61K0009-22 [I,C*]; A61K0009-22 [I,A];
              A61K0009-24 [I,C]; A61K0009-24 [I,A]; A61K0009-30 [I,C*];
              A61K0009-32 [I,A]; A61K0009-50 [I,C*]; A61K0009-50 [I,A];
              A61K0009-52 [I,C*]; A61K0009-52 [I,A]; A61P0001-00 [I,C*];
              A61P0001-04 [I,A]; A61P0043-00 [I,C*]; A61P0043-00 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15  ANSWER 14 OF 58  USPATFULL on STN
Full Text
AN     2006:158680  USPATFULL
TI     Solid dosage form comprising proton pump inhibitor and suspension made
       thereof
IN     Persson, Eva, UNITED STATES
       Trofast, Eva, UNITED STATES
PA     AstraZeneca AB (U.S. corporation)
PI     US 2006134210        A1  20060622
AI     US 2005-312869       A1  20051219 (11)
PRAI   US 2004-638435P      20041222 (60)
DT     Utility
FS     APPLICATION
LN.CNT 1002
INCL   INCLM: 424/471.000
NCL    NCLM:  424/471.000
IC     IPCI   A61K0009-24 [I,A]
       IPCR   A61K0009-24 [I,A]; A61K0009-24 [I,C]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15  ANSWER 15 OF 58  USPATFULL on STN
Full Text
AN     2006:136952  USPATFULL
TI     Gastric acid secretion inhibiting composition
IN     Pettersson, Anders, Lilla Edet, SWEDEN
       Nystrom, Christer, Uppsala, SWEDEN
       Hakansson, Yvonne, Uppsala, SWEDEN
PI     US 2006115530        A1  20060601
AI     US 2003-531598       A1  20031015 (10)
       WO 2003-SE1598           20031015
                                20051125  PCT 371 date
PRAI   SE 2002-3065         20021016
DT     Utility
FS     APPLICATION
LN.CNT 1343
INCL   INCLM: 424/470.000
       INCLS: 514/338.000
NCL    NCLM:  424/470.000
       NCLS:  514/338.000
IC     IPCI   A61K0031-4439 [I,A]; A61K0031-4427 [I,C*]; A61K0009-26 [I,A]
       IPCR   A61K0031-4427 [I,C]; A61K0031-4439 [I,A]; A61K0009-00 [I,C*];
              A61K0009-00 [I,A]; A61K0009-16 [N,C*]; A61K0009-16 [N,A];
              A61K0009-20 [I,C*]; A61K0009-20 [I,A]; A61K0009-24 [I,C*];
              A61K0009-24 [I,A]; A61K0009-26 [I,C]; A61K0009-26 [I,A];
              A61K0009-48 [I,C*]; A61K0009-48 [I,A]; A61K0009-50 [I,C*];
              A61K0009-50 [I,A]; A61K0031-341 [I,C*]; A61K0031-341 [I,A];
```

A61K0031-4164 [I,C*]; A61K0031-4164 [I,A]; A61K0031-426 [I,C*];
A61K0031-426 [I,A]; A61K0045-00 [I,C*]; A61K0045-06 [I,A];
A61P0001-00 [I,C*]; A61P0001-04 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 16 OF 58 USPATFULL on STN
Full Text
AN 2006:124305 USPATFULL
TI Taste-masked pharmaceutical compositions prepared by coacervation
IN Lai, Jin-Wang, Springboro, OH, UNITED STATES
Qian, Ken Kangyi, Cincinnati, OH, UNITED STATES
Venkatesh, Gopi M., Vandalia, OH, UNITED STATES
PA EURAND PHARMACEUTICALS LIMITED (U.S. corporation)
PI US 2006105038 A1 20060518
AI US 2005-213266 A1 20050826 (11)
PRAI US 2004-627525P 20041112 (60)
DT Utility
FS APPLICATION
LN.CNT 1147
INCL INCLM: 424/470.000
NCL NCLM: 424/470.000
IC IPCI A61K0009-26 [I,A]
IPCR A61K0009-26 [I,A]; A61K0009-26 [I,C]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 17 OF 58 USPATFULL on STN
Full Text
AN 2006:92487 USPATFULL
TI Taste-masked pharmaceutical compositions
IN Venkatesh, Gopi M., Vandalia, OH, UNITED STATES
PI US 2006078614 A1 20060413
AI US 2005-248596 A1 20051012 (11)
PRAI US 2004-617737P 20041012 (60)
DT Utility
FS APPLICATION
LN.CNT 1009
INCL INCLM: 424/469.000
NCL NCLM: 424/469.000
IC IPCI A61K0009-26 [I,A]
IPCR A61K0009-26 [I,A]; A61K0009-26 [I,C]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 18 OF 58 USPATFULL on STN
Full Text
AN 2006:60256 USPATFULL
TI Stable pharmaceutical formulations of benzimidazole compounds
IN Shterman, Nava, Petach Tikva, ISRAEL
Capua, Simona Di, Kfar Saba, ISRAEL
Moshe, Benny, Kfar Saba, ISRAEL
Itah, Esther, Netanya, ISRAEL
PI US 2006051421 A1 20060309
AI US 2005-153954 A1 20050615 (11)
PRAI US 2004-580273P 20040615 (60)
US 2004-588233P 20040714 (60)
US 2004-591784P 20040727 (60)
DT Utility
FS APPLICATION
LN.CNT 913
INCL INCLM: 424/472.000
INCLS: 514/338.000
NCL NCLM: 424/472.000
NCLS: 514/338.000
IC IPCI A61K0031-4439 [I,A]; A61K0031-4427 [I,C*]; A61K0009-24 [I,A]
IPCR A61K0031-4427 [I,C]; A61K0031-4439 [I,A]; A61K0009-24 [I,C];
A61K0009-24 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 19 OF 58 USPATFULL on STN
Full Text
AN 2006:53564 USPATFULL
TI Controlled regional oral delivery
IN Jacob, Jules S., Taunton, MA, UNITED STATES

```
       Mathiowitz, Edith, Brookline, MA, UNITED STATES
       Nangia, Avinash, Wrentham, MA, UNITED STATES
       Shaked, Ze'ev, San Antonio, TX, UNITED STATES
       Moslemy, Peyman, Providence, RI, UNITED STATES
PA     Spherics, Inc. (U.S. corporation)
PI     US 2006045865       A1  20060302
AI     US 2005-214206      A1  20050828 (11)
PRAI   US 2004-604990P     20040827 (60)
       US 2004-605198P     20040827 (60)
       US 2004-605199P     20040827 (60)
       US 2004-605200P     20040827 (60)
       US 2004-605201P     20040827 (60)
       US 2004-607905P     20040908 (60)
       US 2005-650191P     20050204 (60)
       US 2005-650375P     20050204 (60)
DT     Utility
FS     APPLICATION
LN.CNT 2229
INCL   INCLM: 424/078.270
NCL    NCLM:  424/078.270
IC     IPCI   A61K0031-74 [I,A]
       IPCR   A61K0031-74 [I,A]; A61K0031-74 [I,C]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15  ANSWER 20 OF 58  USPATFULL on STN
Full Text
AN     2006:27533  USPATFULL
TI     Composition comprising a benzimidazole and process for its manufacture
IN     Seth, Pawan, Irvine, CA, UNITED STATES
PI     US 2006024362       A1  20060202
AI     US 2004-901898      A1  20040729 (10)
DT     Utility
FS     APPLICATION
LN.CNT 648
INCL   INCLM: 424/464.000
       INCLS: 514/394.000
NCL    NCLM:  424/464.000
       NCLS:  514/394.000
IC     IPCI   A61K0009-20 [I,A]; A61K0031-4184 [I,A]; A61K0031-4164 [I,C*]
       IPCR   A61K0009-20 [I,A]; A61K0009-20 [I,C]; A61K0031-4164 [I,C];
              A61K0031-4184 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15  ANSWER 21 OF 58  USPATFULL on STN
Full Text
AN     2006:15490  USPATFULL
TI     Controlled release preparation
IN     Akiyama, Yohko, Osaka-shi Osaka, JAPAN
       Kurasawa, Takashi, Osaka-shi Osaka, JAPAN
       Bando, Hiroto, Osaka-shi Osaka, JAPAN
       Nagahara, Naoki, Osaka-shi Osaka, JAPAN
PI     US 2006013868       A1  20060119
AI     US 2003-531069      A1  20031015 (10)
       WO 2003-JP13155         20031015
                               20050411  PCT 371 date
PRAI   JP 2002-301876      20021016
       JP 2003-66336       20030312
DT     Utility
FS     APPLICATION
LN.CNT 7380
INCL   INCLM: 424/458.000
NCL    NCLM:  424/458.000
IC     IPCI   A61K0009-54 [I,A]; A61K0009-52 [I,C*]
       IPCR   A61K0009-52 [I,C]; A61K0009-54 [I,A]; A61K0009-20 [I,C*];
              A61K0009-20 [I,A]; A61K0009-28 [I,C*]; A61K0009-28 [I,A];
              A61K0009-50 [I,C*]; A61K0009-50 [I,A]; A61K0031-4427 [I,C*];
              A61K0031-4439 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15  ANSWER 22 OF 58  USPATFULL on STN
Full Text
AN     2005:247176  USPATFULL
```

TI Stable pharmaceutical composition comprising an acid labile drug
IN Di Capua, Simona, Kfar Saba, ISRAEL
Shterman, Nava, Petach Tikva, ISRAEL
Ari-Pardo, Limor, Israel, ISRAEL
Itah, Esther, Netanya, ISRAEL
PI US 2005214371 A1 20050929
AI US 2005-68881 A1 20050302 (11)
PRAI US 2004-549653P 20040303 (60)
DT Utility
FS APPLICATION
LN.CNT 1099
INCL INCLM: 424/472.000
INCLS: 514/338.000
NCL NCLM: 424/472.000
NCLS: 514/338.000
IC [7]
ICM A61K031-4439
ICS A61K009-24
IPCI A61K0031-4439 [ICM,7]; A61K0031-4427 [ICM,7,C*]; A61K0009-24 [ICS,7]
IPCR A61K0009-16 [I,C*]; A61K0009-16 [I,A]; A61K0009-24 [I,C*]; A61K0009-24 [I,A]; A61K0009-50 [I,C*]; A61K0009-50 [I,A]; A61K0031-4427 [I,C*]; A61K0031-4439 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 23 OF 58 USPATFULL on STN
Full Text
AN 2005:240133 USPATFULL
TI Gastrointestinal-specific multiple drug release system
IN Tsutsumi, Keiko, Norman, OK, UNITED STATES
Chu, James S., Norman, OK, UNITED STATES
PA Yamanouchi Pharma Technologies, Inc., Norman, OK, UNITED STATES (U.S. corporation)
PI US 2005208133 A1 20050922
AI US 2005-46517 A1 20050127 (11)
PRAI US 2004-540682P 20040129 (60)
DT Utility
FS APPLICATION
LN.CNT 1837
INCL INCLM: 424/472.000
NCL NCLM: 424/472.000
IC [7]
ICM A61K009-48
ICS A61K009-24
IPCI A61K0009-48 [ICM,7]; A61K0009-24 [ICS,7]
IPCR A61K0009-24 [I,C*]; A61K0009-24 [I,A]; A61K0009-48 [I,C*]; A61K0009-48 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 24 OF 58 USPATFULL on STN
Full Text
AN 2005:74741 USPATFULL
TI Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof
IN Heese, Gerd-Ulfert, Munich, GERMANY, FEDERAL REPUBLIC OF
Junger, Herbert, Dachau, GERMANY, FEDERAL REPUBLIC OF
Laicher, Arnim, Sauerlach, GERMANY, FEDERAL REPUBLIC OF
Lorck, Claudio, Munich, GERMANY, FEDERAL REPUBLIC OF
Profitlich, Thomas, Munich, GERMANY, FEDERAL REPUBLIC OF
Weiss, Gerd, Munich, GERMANY, FEDERAL REPUBLIC OF
PI US 2005064035 A1 20050324
AI US 2003-665081 A1 20030916 (10)
RLI Continuation of Ser. No. US 2001-947166, filed on 5 Sep 2001, GRANTED, Pat. No. US 6623759 Continuation of Ser. No. US 1998-219985, filed on 23 Dec 1998, ABANDONED Continuation of Ser. No. WO 1997-EP3387, filed on 27 Jun 1997, UNKNOWN
PRAI DE 1996-19626045 19960628
DT Utility
FS APPLICATION
LN.CNT 980
INCL INCLM: 424/472.000
INCLS: 514/338.000

```
NCL     NCLM:  424/472.000
        NCLS:  514/338.000
IC      [7]
        ICM    A61K031-4439
        ICS    A61K009-24
        IPCI   A61K0031-4439 [ICM,7]; A61K0031-4427 [ICM,7,C*]; A61K0009-24
               [ICS,7]
        IPCR   A61K0009-50 [I,C*]; A61K0009-50 [I,A]; A61K0031-4427 [I,C*];
               A61K0031-4439 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15  ANSWER 25 OF 58  USPATFULL on STN
Full Text
AN      2005:3902  USPATFULL
TI      Granules containing acid-unstable chemical in large amount
IN      Shimizu, Toshihiro, Itami-shi, JAPAN
        Nakano, Yoshinori, Takarazuka-shi, JAPAN
PI      US 2005003005        A1  20050106
AI      US 2004-492690       A1  20040415 (10)
        WO 2002-JP10720          20021016
PRAI    JP 2001-319444       20011017
DT      Utility
FS      APPLICATION
LN.CNT 1331
INCL    INCLM: 424/471.000
        INCLS: 514/338.000
NCL     NCLM:  424/471.000
        NCLS:  514/338.000
IC      [7]
        ICM    A61K009-24
        ICS    A61K031-4439
        IPCI   A61K0009-24 [ICM,7]; A61K0031-4439 [ICS,7]; A61K0031-4427
               [ICS,7,C*]
        IPCR   A61K0009-16 [I,C*]; A61K0009-16 [I,A]; A61K0009-26 [I,C*];
               A61K0009-26 [I,A]; A61K0009-50 [I,C*]; A61K0009-50 [I,A];
               A61K0031-00 [I,C*]; A61K0031-00 [I,A]; A61K0031-4164 [I,C*];
               A61K0031-4184 [I,A]; A61K0031-4427 [I,C*]; A61K0031-4439 [I,A];
               A61P0001-00 [I,C*]; A61P0001-04 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15  ANSWER 26 OF 58  USPATFULL on STN
Full Text
AN      2004:334292  USPATFULL
TI      Oral multi-functional pharmaceutical capsule preparations of proton pump
        inhibitors
IN      Odidi, Isa, Toronto, CANADA
        Odidi, Amina, Toronto, CANADA
PI      US 20042653700       A1  20041230
AI      US 2004-861809       A1  20040604 (10)
PRAI    US 2003-482439P      20030626 (60)
        US 2004-548903P      20040302 (60)
DT      Utility
FS      APPLICATION
LN.CNT 1317
INCL    INCLM: 424/452.000
        INCLS: 424/454.000
NCL     NCLM:  424/452.000
        NCLS:  424/454.000
IC      [7]
        ICM    A61K009-48
        IPCI   A61K0009-48 [ICM,7]
        IPCR   A61K0009-16 [N,C*]; A61K0009-16 [N,A]; A61K0009-20 [I,C*];
               A61K0009-20 [I,A]; A61K0009-28 [I,C*]; A61K0009-28 [I,A];
               A61K0009-50 [I,C*]; A61K0009-50 [I,A]; A61K0031-00 [I,C*];
               A61K0031-00 [I,A]; A61K0031-44 [I,C*]; A61K0031-44 [I,A];
               A61K0031-4427 [I,C*]; A61K0031-4439 [I,A]; A61K0045-00 [I,C*];
               A61K0045-06 [I,A]; A61P0001-00 [I,C*]; A61P0001-04 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15  ANSWER 27 OF 58  USPATFULL on STN
Full Text
AN      2004:279911  USPATFULL
```

```
TI      Pharmeceutical formulation comprising a proton pump inhibitor and
        antacids
IN      Criere, Bruno, Gravigny, FRANCE
        Nouri, Nourredine, Cannes, FRANCE
        Pilbrant, Ake, Kungsbacka, SWEDEN
        Suplie, Pascal, Montaure, FRANCE
        Zuccarelli, Jean-Marc, Antibes, FRANCE
PI      US 2004219211       A1  20041104
AI      US 2004-484064      A1  20040526 (10)
        WO 2002-SE1370          20020710
PRAI    EP 2001-401896      20010716
DT      Utility
FS      APPLICATION
LN.CNT 997
INCL    INCLM: 424/469.000
        INCLS: 514/338.000
NCL     NCLM:  424/469.000
        NCLS:  514/338.000
IC      [7]
        ICM    A61K009-26
        IPCI   A61K0009-26 [ICM,7]
        IPCR   A61K0009-00 [I,C*]; A61K0009-00 [I,A]; A61K0009-16 [I,C*];
               A61K0009-16 [I,A]; A61K0009-20 [N,C*]; A61K0009-20 [N,A];
               A61K0009-26 [I,C*]; A61K0009-26 [I,A]; A61K0009-50 [N,C*];
               A61K0009-50 [N,A]; A61K0031-4427 [I,C*]; A61K0031-4439 [I,A];
               A61K0033-06 [I,C*]; A61K0033-06 [I,A]; A61K0033-08 [I,A];
               A61K0033-10 [I,A]; A61K0045-00 [I,C*]; A61K0045-06 [I,A];
               A61K0047-02 [I,C*]; A61K0047-02 [I,A]; A61K0047-04 [I,A];
               A61K0047-10 [I,C*]; A61K0047-10 [I,A]; A61K0047-12 [I,C*];
               A61K0047-12 [I,A]; A61K0047-14 [I,C*]; A61K0047-14 [I,A];
               A61K0047-16 [I,C*]; A61K0047-16 [I,A]; A61K0047-20 [I,C*];
               A61K0047-20 [I,A]; A61K0047-32 [I,C*]; A61K0047-32 [I,A];
               A61K0047-38 [I,C*]; A61K0047-38 [I,A]; A61K0047-42 [I,C*];
               A61K0047-42 [I,A]; A61P0001-00 [I,C*]; A61P0001-04 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15  ANSWER 28 OF 58  USPATFULL on STN
Full Text
AN      2004:215056  USPATFULL
TI      Novel pharmaceutical formulation containing a proton pump inhibitor and
        an antacid
IN      Niecestro, Robert, Pocono Pines, PA, UNITED STATES
        Kositprapa, Unchalee, Davie, FL, UNITED STATES
        Oh, Yoon, Pembroke Pines, FL, UNITED STATES
        Nangia, Avinash, Weston, FL, UNITED STATES
        Cardinal, John R., Tamarac, FL, UNITED STATES
        Hahn, Elliot F., North Miami Beach, FL, UNITED STATES
PI      US 2004166162       A1  20040826
AI      US 2004-761805      A1  20040121 (10)
PRAI    US 2003-442337P     20030124 (60)
DT      Utility
FS      APPLICATION
LN.CNT 1055
INCL    INCLM: 424/472.000
        INCLS: 514/339.000
NCL     NCLM:  424/472.000
        NCLS:  514/339.000
IC      [7]
        ICM    A61K031-4439
        ICS    A61K009-24
        IPCI   A61K0031-4439 [ICM,7]; A61K0031-4427 [ICM,7,C*]; A61K0009-24
               [ICS,7]
        IPCR   A61K0009-24 [I,C*]; A61K0009-24 [I,A]; A61K0031-4427 [I,C*];
               A61K0031-4439 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15  ANSWER 29 OF 58  USPATFULL on STN
Full Text
AN      2004:171514  USPATFULL
TI      Method of manufacturing tablet
IN      Yamamoto, Keiichi, Hyogo, JAPAN
        Mizukami, Yoshio, Hyogo, JAPAN
```

```
      Izutsu, Daisuke, Dublin, IRELAND
PI    US 2004131675       A1  20040708
AI    US 2003-477478      A1  20031112 (10)
      WO 2002-JP6087          20020619
PRAI  JP 2001-186433      20010620
DT    Utility
FS    APPLICATION
LN.CNT 1642
INCL  INCLM: 424/465.000
      INCLS: 264/109.000; 264/123.000
NCL   NCLM:  424/465.000
      NCLS:  264/109.000; 264/123.000
IC    [7]
      ICM    B29C067-24
      ICS    A61K009-20
      IPCI   B29C067-24 [ICM,7]; A61K0009-20 [ICS,7]
      IPCR   A61J0003-00 [I,C*]; A61J0003-00 [I,A]; A61J0003-10 [I,C*];
             A61J0003-10 [I,A]; A61K0009-00 [I,C*]; A61K0009-00 [I,A];
             A61K0009-24 [I,C*]; A61K0009-24 [I,A]; A61K0009-50 [N,C*];
             A61K0009-50 [N,A]; B30B0011-02 [I,C*]; B30B0011-08 [I,A];
             B30B0015-34 [I,C*]; B30B0015-34 [I,A]

L15  ANSWER 30 OF 58  USPATFULL on STN
Full Text
AN    2004:108112  USPATFULL
TI    Methods for treatment of helicobacter pylori-associated disorders
IN    Chowers, Yehuda, Moshav Zofit, ISRAEL
      Glozman, Sabina, Rehovot, ISRAEL
PI    US 2004082514       A1  20040429
      US 7271146          B2  20070918
AI    US 2003-682937      A1  20031014 (10)
PRAI  IL 2002-152289      20021014
DT    Utility
FS    APPLICATION
LN.CNT 1186
INCL  INCLM: 514/012.000
      INCLS: 514/338.000
NCL   NCLM:  514/002.000; 514/012.000
      NCLS:  424/009.100; 435/007.100; 435/243.000; 514/012.000; 514/017.000;
             514/018.000; 530/300.000; 514/338.000
IC    [7]
      ICM    A61K038-17
      ICS    A61K031-4439
      IPCI   A61K0038-17 [ICM,7]; A61K0031-4439 [ICS,7]; A61K0031-4427
             [ICS,7,C*]
      IPCI-2 A61K0038-00 [I,A]; A61K0049-00 [I,A]
      IPCR   A61K0038-00 [I,C]; A61K0038-00 [I,A]; A61K [I,S]; A61K0031-4427
             [I,C*]; A61K0031-4439 [I,A]; A61K0038-17 [I,C*]; A61K0038-17
             [I,A]; A61K0038-22 [I,C*]; A61K0038-22 [I,A]; A61K0049-00 [I,C];
             A61K0049-00 [I,A]; A61P0001-00 [I,C*]; A61P0001-04 [I,A];
             A61P0031-00 [I,C*]; A61P0031-04 [I,A]; C07K [I,S]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15  ANSWER 31 OF 58  USPATFULL on STN
Full Text
AN    2004:82352  USPATFULL
TI    Maximizing effectiveness of substances used to improve health and well
      being
IN    Hermelin, Victor M., Chesterfield, MI, UNITED STATES
PI    US 2004062802       A1  20040401
AI    US 2003-644041      A1  20030820 (10)
RLI   Continuation of Ser. No. US 1999-475992, filed on 30 Dec 1999, PENDING
      Continuation-in-part of Ser. No. US 1999-323158, filed on 1 Jun 1999,
      GRANTED, Pat. No. US 6214379 Continuation of Ser. No. US 1998-53487,
      filed on 2 Apr 1998, GRANTED, Pat. No. US 5945123
DT    Utility
FS    APPLICATION
LN.CNT 3143
INCL  INCLM: 424/468.000
NCL   NCLM:  424/468.000
IC    [7]
      ICM    A61K009-22
```

```
       IPCI   A61K0009-22 [ICM,7]
       IPCR   A61K0009-22 [I,C*]; A61K0009-22 [I,A]; A61K0031-275 [I,C*];
              A61K0031-277 [I,A]; A61K0031-4164 [I,C*]; A61K0031-4164 [I,A];
              A61K0031-4458 [I,C*]; A61K0031-4458 [I,A]; A61K0031-517 [I,C*];
              A61K0031-517 [I,A]; A61K0031-549 [I,C*]; A61K0031-549 [I,A];
              A61K0031-551 [I,C*]; A61K0031-5513 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15  ANSWER 32 OF 58  USPATFULL on STN
Full Text
AN     2004:57067  USPATFULL
TI     Stable oral formulation containing benzimidazole derivative
IN     Vanderbist, Francis, Bruxelles, BELGIUM
       Sereno, Antonio, Melsbroek, BELGIUM
       Baudier, Philippe, Uccle, BELGIUM
PI     US 2004043069        A1  20040304
AI     US 2003-399482       A1  20030418 (10)
       WO 2001-BE184            20011018
PRAI   WO 2000-BE126       20001020
DT     Utility
FS     APPLICATION
LN.CNT 548
INCL   INCLM: 424/471.000
NCL    NCLM:  424/471.000
IC     [7]
       ICM    A61K009-24
       IPCI   A61K0009-24 [ICM,7]
       IPCR   A61K0009-20 [I,C*]; A61K0009-20 [I,A]; A61K0009-28 [I,C*];
              A61K0009-28 [I,A]; A61K0031-352 [I,C*]; A61K0031-355 [I,A];
              A61K0031-44 [I,C*]; A61K0031-44 [I,A]; A61K0031-4427 [I,C*];
              A61K0031-4439 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15  ANSWER 33 OF 58  USPATFULL on STN
Full Text
AN     2004:38201  USPATFULL
TI     Enteric coated stable oral pharmaceutical composition of acid unstable
       drug and process for preparing the same
IN     Deshpande, Jayant Venkatesh, Maharashtra, INDIA
       Gupte, Vandana Sandeep, Maharashtra, INDIA
       Kadam, Vaishali Madhukar, Maharashtra, INDIA
       Gosar, Chandrakant Thakarsi, Maharashtra, INDIA
       Deshmukh, Satish Ramachandra, Maharashtra, INDIA
       Gupte, Rajan Vitthal, Maharashtra, INDIA
       Tamhankar, Vijay Ramachandra, Maharashtra, INDIA
PA     Kopran Research Laboratories Limited, Maharashtra, INDIA (non-U.S.
       corporation)
PI     US 2004028737        A1  20040212
AI     US 2002-216315       A1  20020812 (10)
DT     Utility
FS     APPLICATION
LN.CNT 612
INCL   INCLM: 424/474.000
       INCLS: 514/338.000
NCL    NCLM:  424/474.000
       NCLS:  514/338.000
IC     [7]
       ICM    A61K031-4439
       ICS    A61K009-16; A61K009-50
       IPCI   A61K0031-4439 [ICM,7]; A61K0031-4427 [ICM,7,C*]; A61K0009-16
              [ICS,7]; A61K0009-50 [ICS,7]
       IPCR   A61K0009-28 [I,C*]; A61K0009-28 [I,A]; A61K0009-50 [I,C*];
              A61K0009-50 [I,A]; A61K0031-4427 [I,C*]; A61K0031-4439 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15  ANSWER 34 OF 58  USPATFULL on STN
Full Text
AN     2004:30709  USPATFULL
TI     Oral pharmaceutical dosage forms comprising a proton pump inhibitor and
       a NSAID
IN     Depui, Helene, Goteborg, SWEDEN
       Lundberg, Per, Molndal, SWEDEN
```

```
PI     US 2004022846       A1  20040205
AI     US 2003-620000      A1  20030714 (10)
RLI    Continuation of Ser. No. US 2002-90882, filed on 4 Mar 2002, GRANTED,
       Pat. No. US 6613354 Continuation of Ser. No. US 1999-471958, filed on 23
       Dec 1999, GRANTED, Pat. No. US 6365184 Continuation of Ser. No. US
       1997-793078, filed on 13 Feb 1997, ABANDONED A 371 of International Ser.
       No. WO 1996-SE1735, filed on 20 Dec 1996, UNKNOWN
PRAI   SE 1996-70          19960108
DT     Utility
FS     APPLICATION
LN.CNT 1465
INCL   INCLM: 424/452.000
       INCLS: 424/465.000; 514/338.000
NCL    NCLM:  424/452.000
       NCLS:  424/465.000; 514/338.000
IC     [7]
       ICM    A61K031-4439
       ICS    A61K009-48; A61K009-20
       IPCI   A61K0031-4439 [ICM,7]; A61K0031-4427 [ICM,7,C*]; A61K0009-48
              [ICS,7]; A61K0009-20 [ICS,7]
       IPCR   A61K0009-20 [I,C*]; A61K0009-20 [I,A]; A61K0009-24 [I,C*];
              A61K0009-24 [I,A]; A61K0009-28 [I,C*]; A61K0009-28 [I,A];
              A61K0009-50 [I,C*]; A61K0009-50 [I,A]; A61K0045-00 [I,C*];
              A61K0045-06 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15  ANSWER 35 OF 58  USPATFULL on STN
Full Text
AN     2003:288260  USPATFULL
TI     Stable oral pharmaceutical dosage forms
IN     Chen, Jivn-Ren, Shreveport, LA, UNITED STATES
PA     Sage Pharmaceuticals, Inc. (U.S. corporation)
PI     US 2003203038       A1  20031030
       US 7041316          B2  20060509
AI     US 2003-422338      A1  20030424 (10)
RLI    Division of Ser. No. US 1998-141476, filed on 27 Aug 1998, PENDING
       Continuation-in-part of Ser. No. US 1997-950432, filed on 15 Oct 1997,
       ABANDONED
PRAI   WO 1998-US9449      19980508
       US 1997-46089P      19970509 (60)
DT     Utility
FS     APPLICATION
LN.CNT 633
INCL   INCLM: 424/452.000
NCL    NCLM:  424/463.000; 424/452.000
       NCLS:  424/451.000; 424/456.000; 424/464.000; 424/474.000; 424/478.000;
              424/480.000; 424/482.000; 424/489.000; 514/925.000; 514/962.000
IC     [7]
       ICM    A61K009-48
       IPCI   A61K0009-48 [ICM,7]
       IPCI-2 A61L0009-48 [I,A]; A61L0009-64 [I,A]; A61L0009-20 [I,A];
              A61L0009-18 [I,C*]; A61L0009-32 [I,A]; A61L0009-14 [I,A]
       IPCR   A61K0009-30 [I,C]; A61K0009-32 [I,A]; A61K0009-28 [I,C*];
              A61K0009-28 [I,A]; A61K0009-48 [I,C]; A61K0009-48 [I,A];
              A61K0009-52 [I,C]; A61K0009-64 [I,A]; A61K0031-4164 [I,C*];
              A61K0031-4184 [I,A]; A61K0031-4427 [I,C*]; A61K0031-4439 [I,A];
              A61L0009-14 [I,C]; A61L0009-18 [I,C]; A61L0009-20 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15  ANSWER 36 OF 58  USPATFULL on STN
Full Text
AN     2003:250574  USPATFULL
TI     Symptomatic relief of gastrointestinal disorders
IN     Luzzatti, Renzo, Weston, FL, UNITED STATES
PI     US 2003175360       A1  20030918
AI     US 2002-79569       A1  20020222 (10)
DT     Utility
FS     APPLICATION
LN.CNT 2408
INCL   INCLM: 424/653.000
       INCLS: 424/682.000; 424/691.000; 514/304.000; 514/503.000; 514/537.000
NCL    NCLM:  424/653.000
```

```
      NCLS:  424/682.000; 424/691.000; 514/304.000; 514/503.000; 514/537.000
IC    [7]
      ICM    A61K031-46
      ICS    A61K031-29; A61K033-08; A61K033-06; A61K033-24
      IPCI   A61K0031-46 [ICM,7]; A61K0031-29 [ICS,7]; A61K0031-28 [ICS,7,C*];
             A61K0033-08 [ICS,7]; A61K0033-06 [ICS,7]; A61K0033-24 [ICS,7]
      IPCR   A61K0031-00 [I,C*]; A61K0031-00 [I,A]; A61K0033-06 [I,C*];
             A61K0033-06 [I,A]; A61K0033-24 [I,C*]; A61K0033-24 [I,A];
             A61K0045-00 [I,C*]; A61K0045-06 [I,A]; A61P0001-00 [I,C*];
             A61P0001-04 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15  ANSWER 37 OF 58  USPATFULL on STN
Full Text
AN    2003:209868  USPATFULL
TI    Pharmaceutical formulation for acid-labile compounds
IN    Chen, Chih-Ming, Davie, FL, United States
      Chou, Joseph, Coral Springs, FL, United States
      Kositprapa, Unchalee, Fort Lauderdale, FL, United States
PA    Andrx Pharmaceuticals L.L.C., Davie, FL, United States (U.S.
      corporation)
PI    US 6602522          B1  20030805
AI    US 2000-597206          20000620 (9)
RLI   Continuation-in-part of Ser. No. US 1999-335575, filed on 18 Jun 1999,
      now patented, Pat. No. US 6077541 Division of Ser. No. US 1997-970489,
      filed on 14 Nov 1997, now patented, Pat. No. US 6096340
      Continuation-in-part of Ser. No. US 1998-143167, filed on 28 Aug 1998,
      now patented, Pat. No. US 6174548
DT    Utility
FS    GRANTED
LN.CNT 508
INCL  INCLM: 424/480.000
      INCLS: 424/474.000; 424/475.000; 424/476.000; 424/479.000
NCL   NCLM:  424/480.000
      NCLS:  424/474.000; 424/475.000; 424/476.000; 424/479.000
IC    [7]
      ICM    A61K009-36
      ICS    A61K009-14; A61K009-24; A61K009-28; A61K009-30
      IPCI   A61K0009-36 [ICM,7]; A61K0009-14 [ICS,7]; A61K0009-24 [ICS,7];
             A61K0009-28 [ICS,7]; A61K0009-30 [ICS,7]
      IPCR   A61K0009-20 [I,C*]; A61K0009-20 [I,A]; A61K0009-28 [I,C*];
             A61K0009-28 [I,A]; A61K0009-30 [I,C*]; A61K0009-30 [I,A];
             A61K0009-36 [I,A]; A61K0009-50 [I,C*]; A61K0009-50 [I,A];
             A61K0031-4427 [I,C*]; A61K0031-4439 [I,A]
EXF   424/480; 424/479; 424/475; 424/474; 424/476
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15  ANSWER 38 OF 58  USPATFULL on STN
Full Text
AN    2003:187448  USPATFULL
TI    Pharmaceutical formulations containing a non-steroidal antiinflammatory
      drug and a proton pump inhibitor
IN    Chen, Chih-Ming, Davie, FL, UNITED STATES
      Kositprapa, Unchalee, Davie, FL, UNITED STATES
PI    US 2003129235       A1  20030710
      US 6869615          B2  20050322
AI    US 2002-282820      A1  20021028 (10)
RLI   Continuation of Ser. No. US 2000-659222, filed on 11 Sep 2000, PENDING
DT    Utility
FS    APPLICATION
LN.CNT 1271
INCL  INCLM: 424/470.000
NCL   NCLM:  424/469.000; 424/470.000
      NCLS:  424/451.000; 424/452.000; 424/457.000; 424/458.000; 424/465.000;
             424/468.000; 424/470.000; 424/474.000; 424/489.000; 424/490.000
IC    [7]
      ICM    A61K009-26
      IPCI   A61K0009-26 [ICM,7]
      IPCI-2 A61K0009-20 [ICM,7]; A61K0009-22 [ICS,7]; A61K0009-26 [ICS,7];
             A61K0009-28 [ICS,7]; A61K0009-54 [ICS,7]; A61K0009-52 [ICS,7,C*]
      IPCR   A61K0009-22 [I,C*]; A61K0009-22 [I,A]; A61K0009-24 [I,C*];
             A61K0009-24 [I,A]; A61K0009-26 [I,C*]; A61K0009-26 [I,A];
```

A61K0009-28 [N,C*]; A61K0009-28 [N,A]; A61K0009-30 [I,C*];
A61K0009-30 [I,A]; A61K0009-32 [I,A]; A61K0009-34 [I,A];
A61K0009-36 [I,A]; A61K0009-48 [I,C*]; A61K0009-48 [I,A];
A61K0009-50 [N,C*]; A61K0009-50 [N,A]; A61K0009-52 [I,C*];
A61K0009-54 [I,A]; A61K0009-58 [I,A]; A61K0009-60 [I,A];
A61K0009-62 [I,A]; A61K0031-185 [I,C*]; A61K0031-196 [I,A];
A61K0031-415 [I,C*]; A61K0031-415 [I,A]; A61K0031-44 [I,C*];
A61K0031-44 [I,A]; A61K0031-4427 [I,C*]; A61K0031-4439 [I,A];
A61K0045-00 [I,C*]; A61K0045-00 [I,A]; A61K0047-10 [I,C*];
A61K0047-10 [I,A]; A61P0015-00 [I,C*]; A61P0015-00 [I,A];
A61P0019-00 [I,C*]; A61P0019-02 [I,A]; A61P0029-00 [I,C*];
A61P0029-00 [I,A]; A61P0043-00 [I,C*]; A61P0043-00 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 39 OF 58 USPATFULL on STN
Full Text
AN 2003:95840 USPATFULL
TI Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
IN Chen, Chih-Ming, Davie, FL, United States
Kositprapa, Unchalee, Davie, FL, United States
PA Andrx Corporation, Davie, FL, United States (U.S. corporation)
PI US 6544556 B1 20030408
AI US 2000-659222 20000911 (9)
DT Utility
FS GRANTED
LN.CNT 1236
INCL INCLM: 424/469.000
INCLS: 424/451.000; 424/452.000; 424/457.000; 424/458.000; 424/464.000; 424/465.000; 424/470.000; 424/472.000
NCL NCLM: 424/469.000
NCLS: 424/451.000; 424/452.000; 424/457.000; 424/458.000; 424/464.000; 424/465.000; 424/470.000; 424/472.000
IC [7]
ICM A61K009-20
ICS A61K009-22; A61K009-24; A61K009-26; A61K009-54
IPCI A61K0009-20 [ICM,7]; A61K0009-22 [ICS,7]; A61K0009-24 [ICS,7]; A61K0009-26 [ICS,7]; A61K0009-54 [ICS,7]; A61K0009-52 [ICS,7,C*]
IPCR A61K0009-22 [I,C*]; A61K0009-22 [I,A]; A61K0009-24 [I,C*]; A61K0009-24 [I,A]; A61K0009-26 [I,C*]; A61K0009-26 [I,A]; A61K0009-28 [N,C*]; A61K0009-28 [N,A]; A61K0009-30 [I,C*]; A61K0009-30 [I,A]; A61K0009-32 [I,A]; A61K0009-34 [I,A]; A61K0009-36 [I,A]; A61K0009-48 [I,C*]; A61K0009-48 [I,A]; A61K0009-50 [N,C*]; A61K0009-50 [N,A]; A61K0009-52 [I,C*]; A61K0009-54 [I,A]; A61K0009-58 [I,A]; A61K0009-60 [I,A]; A61K0009-62 [I,A]; A61K0031-185 [I,C*]; A61K0031-196 [I,A]; A61K0031-415 [I,C*]; A61K0031-415 [I,A]; A61K0031-44 [I,C*]; A61K0031-44 [I,A]; A61K0031-4427 [I,C*]; A61K0031-4439 [I,A]; A61K0045-00 [I,C*]; A61K0045-00 [I,A]; A61K0047-10 [I,C*]; A61K0047-10 [I,A]; A61P0015-00 [I,C*]; A61P0015-00 [I,A]; A61P0019-00 [I,C*]; A61P0019-02 [I,A]; A61P0029-00 [I,C*]; A61P0029-00 [I,A]; A61P0043-00 [I,C*]; A61P0043-00 [I,A]
EXF 424/451; 424/455; 424/456; 424/464; 424/468; 424/469; 424/470; 424/477; 424/480; 424/481; 424/482; 424/489; 424/493; 424/494; 424/495; 424/496; 424/497; 424/452; 424/472; 424/457; 424/458
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 40 OF 58 USPATFULL on STN
Full Text
AN 2002:279721 USPATFULL
TI Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a NSAID
IN Depui, Helene, Goteborg, SWEDEN
Lundberg, Per, Molndal, SWEDEN
PA AstraZeneca AB. (non-U.S. corporation)
PI US 2002155153 A1 20021024
US 6613354 B2 20030902
AI US 2002-90882 A1 20020304 (10)
RLI Continuation of Ser. No. US 1999-471958, filed on 23 Dec 1999, GRANTED, Pat. No. US 6365184 Continuation of Ser. No. US 1997-793078, filed on 13 Feb 1997, ABANDONED A 371 of International Ser. No. WO 1996-SE1735, filed on 20 Dec 1996, UNKNOWN

```
PRAI   SE 1996-70          19960108
DT     Utility
FS     APPLICATION
LN.CNT 1497
INCL   INCLM: 424/452.000
       INCLS: 424/465.000; 514/338.000
NCL    NCLM:  424/458.000; 424/452.000
       NCLS:  424/451.000; 424/452.000; 424/457.000; 424/465.000; 514/338.000
IC     [7]
       ICM    A61K031-4439
       ICS    A61K009-48; A61K009-20
       IPCI   A61K0031-4439 [ICM,7]; A61K0031-4427 [ICM,7,C*]; A61K0009-48
              [ICS,7]; A61K0009-20 [ICS,7]
       IPCI-2 A61K0009-48 [ICM,7]; A61K0009-52 [ICS,7]; A61K0009-54 [ICS,7];
              A61K0009-52 [ICS,7,C*]
       IPCR   A61K0009-20 [I,C*]; A61K0009-20 [I,A]; A61K0009-24 [I,C*];
              A61K0009-24 [I,A]; A61K0009-28 [I,C*]; A61K0009-28 [I,A];
              A61K0009-50 [I,C*]; A61K0009-50 [I,A]; A61K0009-52 [I,C*];
              A61K0009-52 [I,A]; A61K0009-54 [I,A]; A61K0045-00 [I,C*];
              A61K0045-06 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15  ANSWER 41 OF 58  USPATFULL on STN
Full Text
AN     2002:258467  USPATFULL
TI     Orally disintegrable tablets
IN     Shimizu, Toshihiro, Itami-shi, JAPAN
       Morimoto, Shuji, Osaka, JAPAN
       Tabata, Tetsuro, Osaka, JAPAN
PI     US 2002142034       A1  20021003
AI     US 2001-17755       A1  20011030 (10)
RLI    Continuation of Ser. No. US 1999-355781, filed on 4 Aug 1999, GRANTED,
       Pat. No. US 6328994 A 371 of International Ser. No. WO 1999-JP2548,
       filed on 17 May 1999, UNKNOWN
PRAI   JP 1998-135472      19980518
       JP 1998-219266      19980803
       JP 1998-222151      19980805
       JP 1999-5144        19990112
       JP 1999-15851       19990125
DT     Utility
FS     APPLICATION
LN.CNT 2241
INCL   INCLM: 424/470.000
       INCLS: 514/338.000
NCL    NCLM:  424/470.000
       NCLS:  514/338.000
IC     [7]
       ICM    A61K031-4439
       ICS    A61K009-26; A61K009-14
       IPCI   A61K0031-4439 [ICM,7]; A61K0031-4427 [ICM,7,C*]; A61K0009-26
              [ICS,7]; A61K0009-14 [ICS,7]
       IPCR   A61K0009-00 [I,C*]; A61K0009-00 [I,A]; A61K0009-20 [I,C*];
              A61K0009-20 [I,A]; A61K0009-26 [I,C*]; A61K0009-26 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15  ANSWER 42 OF 58  USPATFULL on STN
Full Text
AN     2002:115818  USPATFULL
TI     Pharmaceutical formulation comprising a 2- [(2-pyridinyl) methyl]
       sulfinyl benzimidazole having anti-ulcer activity and a process for the
       preparation of such formulation
IN     Henriksen, Kristian Lund, S.o slashed.borg, DENMARK
       Kann, Helle, Frederiksberg, DENMARK
       S.o slashed.rensen, Karen Eichstedt, Valby, DENMARK
       Pedersen, S.o slashed.ren Bols, Hvidovre, DENMARK
PA     A/S GEA Farmaceutisk Fabrik, Frederiksberg, DENMARK (non-U.S.
       corporation)
PI     US 6391342          B1  20020521
       WO 9948498  19990930
AI     US 2000-646486          20000919 (9)
       WO 1999-DK137           19990317
                               20000919  PCT 371 date
```

PRAI DK 1998-397 19980320
DT Utility
FS GRANTED
LN.CNT 763
INCL INCLM: 424/490.000
INCLS: 424/457.000; 424/458.000; 424/456.000; 424/489.000; 424/498.000
NCL NCLM: 424/490.000
NCLS: 424/456.000; 424/457.000; 424/458.000; 424/489.000; 424/498.000
IC [7]
ICM A61K009-50
ICS A61K009-16; A61K009-52; A61K009-64; A61K009-54
IPCI A61K0009-50 [ICM,7]; A61K0009-16 [ICS,7]; A61K0009-52 [ICS,7];
A61K0009-64 [ICS,7]; A61K0009-54 [ICS,7]; A61K0009-52 [ICS,7,C*]
IPCR A61K0009-50 [I,C*]; A61K0009-50 [I,A]; A61K0009-52 [I,C*];
A61K0009-52 [I,A]; A61K0009-54 [I,A]; A61K0009-64 [I,A];
A61K0031-4427 [I,C*]; A61K0031-4439 [I,A]
EXF 424/490; 424/457; 424/458; 424/456; 424/502; 424/489
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 43 OF 58 USPATFULL on STN
Full Text
AN 2002:105711 USPATFULL
TI Stable drug from for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof
IN Heese, Gerd-Ulfert, Munich, GERMANY, FEDERAL REPUBLIC OF
Junger, Herbert, Dachau, GERMANY, FEDERAL REPUBLIC OF
Laicher, Arnim, Sauerlach, GERMANY, FEDERAL REPUBLIC OF
Lorck, Claudio, Munich, GERMANY, FEDERAL REPUBLIC OF
Profitlich, Thomas, Munich, GERMANY, FEDERAL REPUBLIC OF
Weiss, Gerd, Munich, GERMANY, FEDERAL REPUBLIC OF
PI US 2002054913 A1 20020509
US 6623759 B2 20030923
AI US 2001-947166 A1 20010905 (9)
RLI Continuation of Ser. No. US 1998-219985, filed on 23 Dec 1998, ABANDONED
PRAI DE 1996-19626045 19960628
DT Utility
FS APPLICATION
LN.CNT 989
INCL INCLM: 424/490.000
NCL NCLM: 424/480.000; 424/490.000
NCLS: 424/461.000; 424/462.000; 424/472.000; 424/475.000; 424/482.000; 424/490.000; 424/494.000; 424/497.000; 514/772.300; 514/781.000
IC [7]
ICM A61K009-16
ICS A61K009-50
IPCI A61K0009-16 [ICM,7]; A61K0009-50 [ICS,7]
IPCI-2 A61K0009-24 [ICM,7]; A61K0009-32 [ICS,7]; A61K0009-36 [ICS,7];
A61K0009-30 [ICS,7,C*]; A61K0009-58 [ICS,7]; A61K0009-62 [ICS,7];
A61K0009-52 [ICS,7,C*]
IPCR A61K0009-30 [I,C*]; A61K0009-32 [I,A]; A61K0009-36 [I,A];
A61K0009-50 [I,C*]; A61K0009-50 [I,A]; A61K0009-52 [I,C*];
A61K0009-58 [I,A]; A61K0009-62 [I,A]; A61K0031-4427 [I,C*];
A61K0031-4439 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 44 OF 58 USPATFULL on STN
Full Text
AN 2002:69628 USPATFULL
TI Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a NSAID
IN Depui, Helene, Goteborg, SWEDEN
Lundberg, Per, Molndal, SWEDEN
PA AstraZeneca AB, Sodertalje, SWEDEN (non-U.S. corporation)
PI US 6365184 B1 20020402
AI US 1999-471958 19991223 (9)
RLI Continuation of Ser. No. US 793078, now abandoned
PRAI SE 1996-70 19960108
DT Utility
FS GRANTED
LN.CNT 1319
INCL INCLM: 424/469.000
INCLS: 424/469.000; 424/468.000; 424/464.000; 424/465.000; 424/472.000;

```
                424/473.000; 424/471.000; 424/470.000; 424/490.000; 424/493.000;
                424/494.000; 514/338.000
NCL     NCLM:   424/469.000
        NCLS:   424/464.000; 424/465.000; 424/468.000; 424/470.000; 424/471.000;
                424/472.000; 424/473.000; 424/490.000; 424/493.000; 424/494.000;
                514/338.000
IC      [7]
        ICM     A61K009-36
        ICS     A61K009-26
        IPCI    A61K0009-36 [ICM,7]; A61K0009-30 [ICM,7,C*]; A61K0009-26 [ICS,7]
        IPCR    C07D0401-00 [I,C*]; C07D0401-12 [I,A]; A61K0009-20 [I,C*];
                A61K0009-20 [I,A]; A61K0009-24 [I,C*]; A61K0009-24 [I,A];
                A61K0009-26 [I,C*]; A61K0009-26 [I,A]; A61K0009-28 [I,C*];
                A61K0009-28 [I,A]; A61K0009-30 [I,C*]; A61K0009-36 [I,A];
                A61K0009-48 [I,C*]; A61K0009-48 [I,A]; A61K0009-50 [I,C*];
                A61K0009-50 [I,A]; A61K0009-52 [I,C*]; A61K0009-54 [I,A];
                A61K0031-185 [I,C*]; A61K0031-19 [I,A]; A61K0031-4164 [I,C*];
                A61K0031-4184 [I,A]; A61K0031-44 [I,C*]; A61K0031-44 [I,A];
                A61K0031-4427 [I,C*]; A61K0031-4427 [I,A]; A61K0045-00 [I,C*];
                A61K0045-06 [I,A]; A61P0031-00 [I,C*]; A61P0031-04 [I,A]
EXF     424/464; 424/465; 424/472; 424/99; 424/473; 424/471; 424/468-469;
        424/470; 424/474; 424/493; 424/494; 424/490; 514/338
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15  ANSWER 45 OF 58  USPATFULL on STN
Full Text
AN      2002:29141  USPATFULL
TI      Method for preparing an oral formulation containing acid-sensitive drugs
        and oral formulation made thereby
IN      Hsiao, Fang-Hsiung, Tainan Hsien, TAIWAN, PROVINCE OF CHINA
        Lin, Chien-Chu, Tainan Hsien, TAIWAN, PROVINCE OF CHINA
        Changchien, Ya-Ching, Kaohsiung, TAIWAN, PROVINCE OF CHINA
PA      Standard Chem. & Pharm. Co., Ltd., Tainan, TAIWAN, PROVINCE OF CHINA
        (non-U.S. corporation)
PI      US 6346269          B1  20020212
AI      US 2000-567083          20000508 (9)
DT      Utility
FS      GRANTED
LN.CNT 703
INCL    INCLM: 424/472.000
        INCLS: 424/464.000; 424/465.000; 424/451.000; 424/458.000
NCL     NCLM:  424/472.000
        NCLS:  424/451.000; 424/458.000; 424/464.000; 424/465.000
IC      [7]
        ICM    A61K009-24
        ICS    A61K009-20; A61K009-48; A61K009-54
        IPCI   A61K0009-24 [ICM,7]; A61K0009-20 [ICS,7]; A61K0009-48 [ICS,7];
               A61K0009-54 [ICS,7]; A61K0009-52 [ICS,7,C*]
        IPCR   A61K0009-50 [I,C*]; A61K0009-50 [I,A]; A61K0009-52 [I,C*];
               A61K0009-54 [I,A]
EXF     424/464; 424/465; 424/458; 424/451; 424/472
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15  ANSWER 46 OF 58  USPATFULL on STN
Full Text
AN      2001:226274  USPATFULL
TI      Orally disintegrable tablets
IN      Shimizu, Toshihiro, Itami, Japan
        Morimoto, Shuji, Suita, Japan
        Tabata, Tetsuro, Suita, Japan
PA      Takeda Chemical Industries, Ltd., Osaka, Japan (non-U.S. corporation)
PI      US 6328994          B1  20011211
        WO 9959544          19991125
AI      US 1999-355781          19990804 (9)
        WO 1999-JP2548          19990517
                                19990804  PCT 371 date
                                19990804  PCT 102(e) date
PRAI    JP 1998-135472      19980518
        JP 1998-219266      19980803
        JP 1998-222151      19980805
        JP 1998-344810      19981029
        JP 1999-5144        19990112
```

```
      JP 1999-15851       19990125
DT    Utility
FS    GRANTED
LN.CNT 2214
INCL  INCLM: 424/489.000
      INCLS: 424/464.000; 424/465.000; 424/466.000; 424/490.000; 424/493.000
NCL   NCLM:  424/489.000
      NCLS:  424/464.000; 424/465.000; 424/466.000; 424/490.000; 424/493.000
IC    [7]
      ICM    A61K009-14
      ICS    A61K009-20; A61K009-46; A61K009-16
      IPCI   A61K0009-14 [ICM,7]; A61K0009-20 [ICS,7]; A61K0009-46 [ICS,7];
             A61K0009-16 [ICS,7]
      IPCR   A61K0009-50 [I,C*]; A61K0009-50 [I,A]; A61K0009-00 [I,C*];
             A61K0009-00 [I,A]; A61K0009-20 [I,C*]; A61K0009-20 [I,A];
             A61K0031-4427 [I,C*]; A61K0031-4439 [I,A]; A61P0001-00 [I,C*];
             A61P0001-04 [I,A]
EXF   424/464; 424/465; 424/466; 424/489; 424/490; 424/493
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15  ANSWER 47 OF 58  USPATFULL on STN
Full Text
AN    2001:105030  USPATFULL
TI    STABLE ORAL PHARMACEUTICAL DOSAGE FORMS
IN    CHEN, JIVN-REN, SHREVEPORT, LA, United States
PI    US 2001006649       A1  20010705
      US 6726927          B2  20040427
AI    US 1998-141476      A1  19980827 (9)
RLI   Continuation of Ser. No. US 1997-950432, filed on 15 Oct 1997, ABANDONED
      A 371 of International Ser. No. WO 1998-US9449, filed on 8 May 1998,
      UNKNOWN
PRAI  US 1997-46089P      19970509 (60)
DT    Utility
FS    APPLICATION
LN.CNT 633
INCL  INCLM: 424/400.000
NCL   NCLM:  424/463.000; 424/400.000
      NCLS:  424/451.000; 424/456.000; 424/464.000; 424/474.000; 424/478.000;
             424/480.000; 424/482.000; 424/489.000; 514/925.000; 514/962.000
IC    [7]
      ICM    A61K009-00
      IPCI   A61K0009-00 [ICM,7]
      IPCI-2 A61L0009-48 [ICM,7]; A61L0009-64 [ICS,7]; A61L0009-20 [ICS,7];
             A61L0009-18 [ICS,7,C*]; A61L0009-32 [ICS,7]; A61L0009-14 [ICS,7]
      IPCR   A61K0009-28 [I,A]; A61K0009-28 [I,C*]; A61K0009-48 [I,A];
             A61K0009-48 [I,C*]; A61K0031-4164 [I,C*]; A61K0031-4184 [I,A];
             A61K0031-4427 [I,C*]; A61K0031-4439 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15  ANSWER 48 OF 58  USPATFULL on STN
Full Text
AN    2001:67211  USPATFULL
TI    Orally administered pharmaceutical formulations of benzimidazole
      derivatives and the method of preparing the same
IN    Lee, Fang-Yu, Taichung, Taiwan, Province of China
      Chen, Shan-chiung, Taichung, Taiwan, Province of China
      Kuo, Han-Chiang, Taichung, Taiwan, Province of China
PA    Carlsbad Technology, Inc., Carlsbad, CA, United States (U.S.
      corporation)
PI    US 6228400          B1  20010508
AI    US 2000-488406          20000119 (9)
PRAI  US 1999-156394P     19990928 (60)
DT    Utility
FS    Granted
LN.CNT 752
INCL  INCLM: 424/489.000
      INCLS: 424/451.000; 424/452.000; 424/490.000; 424/493.000; 424/494.000;
             514/277.000; 514/336.000; 514/337.000; 514/338.000
NCL   NCLM:  424/489.000
      NCLS:  424/451.000; 424/452.000; 424/490.000; 424/493.000; 424/494.000;
             514/277.000; 514/336.000; 514/337.000; 514/338.000
IC    [7]
```

```
       ICM    A61K009-14
       ICS    A61K009-48; A61K009-16; A01N043-40
       IPCI   A61K0009-14 [ICM,7]; A61K0009-48 [ICS,7]; A61K0009-16 [ICS,7];
              A01N0043-40 [ICS,7]; A01N0043-34 [ICS,7,C*]
       IPCR   A61K0009-50 [I,A]; A61K0009-50 [I,C*]; A61K0031-4427 [I,C*];
              A61K0031-4439 [I,A]
EXF    514/277; 514/336; 514/337; 514/338; 424/451; 424/452; 424/489; 424/490;
       424/493; 424/494
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15  ANSWER 49 OF 58  USPATFULL on STN
Full Text
AN     2000:167547  USPATFULL
TI     Composition containing an acid-labile benzimidazole and process for its
       preparation
IN     Seth, Pawan, Irvine, CA, United States
PA     Pharma Pass LLC, Irvine, CA, United States (U.S. corporation)
PI     US 6159499             20001212
       WO 9712580  19970410
AI     US 1998-43663          19981020 (9)
       WO 1996-IB1054         19960923
                              19981020  PCT 371 date
                              19981020  PCT 102(e) date
PRAI   FR 1995-11094       19950921
       FR 1995-14492       19951207
       FR 1996-2265        19960223
       FR 1996-5082        19960423
DT     Utility
FS     Granted
LN.CNT 991
INCL   INCLM: 424/451.000
       INCLS: 424/452.000; 424/457.000; 424/461.000; 424/462.000; 424/468.000;
              424/470.000; 424/474.000; 424/480.000; 424/482.000; 424/458.000;
              514/770.000; 514/784.000; 514/951.000; 514/960.000; 514/962.000;
              514/970.000
NCL    NCLM:  424/451.000
       NCLS:  424/452.000; 424/457.000; 424/458.000; 424/461.000; 424/462.000;
              424/468.000; 424/470.000; 424/474.000; 424/480.000; 424/482.000;
              514/770.000; 514/784.000; 514/951.000; 514/960.000; 514/962.000;
              514/970.000
IC     [7]
       ICM    A61K009-22
       ICS    A61K009-28; A61K009-52; A61K009-54; A61K009-56
       IPCI   A61K0009-22 [ICM,7]; A61K0009-28 [ICS,7]; A61K0009-52 [ICS,7];
              A61K0009-54 [ICS,7]; A61K0009-56 [ICS,7]; A61K0009-52 [ICS,7,C*]
       IPCR   A61K0009-28 [I,A]; A61K0009-28 [I,C*]; A61K0009-48 [I,A];
              A61K0009-48 [I,C*]; A61K0009-50 [I,A]; A61K0009-50 [I,C*];
              A61K0031-4164 [I,C*]; A61K0031-4184 [I,A]; A61K0031-4427 [I,C*];
              A61K0031-4439 [I,A]
EXF    424/468; 424/469; 424/470; 424/474; 424/480; 424/482; 424/451; 424/452;
       424/457; 424/458; 424/461; 424/462; 424/459; 424/475
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15  ANSWER 50 OF 58  USPATFULL on STN
Full Text
AN     2000:141911  USPATFULL
TI     Oral pharmaceutical dosage form
IN     Depui, Helene, Goteborg, Sweden
       Rosinski, Adam, Molndal, Sweden
PA     Astra Aktiebolag, Sodertalje, Sweden (non-U.S. corporation)
PI     US 6136344             20001024
       WO 9624375  19960815
AI     US 1996-628712         19960415 (8)
       WO 1996-SE125          19960202
                              19960415  PCT 371 date
                              19960415  PCT 102(e) date
RLI    Continuation-in-part of Ser. No. US 1995-464775, filed on 7 Jun 1995,
       now abandoned
PRAI   SE 1995-422         19950206
DT     Utility
FS     Granted
LN.CNT 1271
```

```
INCL    INCLM: 424/470.000
        INCLS: 424/464.000; 424/468.000; 424/469.000
NCL     NCLM:  424/470.000
        NCLS:  424/464.000; 424/468.000; 424/469.000
IC      [7]
        ICM    A61K009-26
        ICS    A61K031-33
        IPCI   A61K0009-26 [ICM,7]; A61K0031-33 [ICS,7]
        IPCR   A61K0009-20 [I,A]; A61K0009-20 [I,C*]; A61K0009-28 [I,A];
               A61K0009-28 [I,C*]; A61K0009-50 [I,A]; A61K0009-50 [I,C*];
               A61K0045-00 [I,C*]; A61K0045-06 [I,A]
EXF     424/451; 424/457; 424/458; 424/459; 424/462; 424/464; 424/468; 424/475;
        424/482; 424/469; 424/470; 514/300
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15  ANSWER 51 OF 58  USPATFULL on STN
Full Text
AN      1998:127937  USPATFULL
TI      Effervescent composition and its production
IN      Shimizu, Toshihiro, Hyogo, Japan
        Tabata, Tetsuro, Osaka, Japan
        Kikuta, Junichi, Osaka, Japan
PA      Takeda Chemical Industries, Ltd, Osaka, Japan (non-U.S. corporation)
PI      US 5824339              19981020
AI      US 1996-708663          19960905 (8)
PRAI    JP 1995-257064      19950908
DT      Utility
FS      Granted
LN.CNT 852
INCL    INCLM: 424/466.000
        INCLS: 424/465.000; 427/002.140; 427/002.210
NCL     NCLM:  424/466.000
        NCLS:  424/465.000; 427/002.140; 427/002.210
IC      [6]
        ICM    A61K009-46
        IPCI   A61K0009-46 [ICM,6]
        IPCR   A61K0009-46 [I,C*]; A61K0009-46 [I,A]
EXF     424/466; 424/465; 427/2.14; 427/2.21
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15  ANSWER 52 OF 58  USPATFULL on STN
Full Text
AN      1998:74829  USPATFULL
TI      Device for mixing a pharmaceutical composition with an other agent
IN      Glad, HÅkan Lars Christer, Åsa, Sweden
        Kers, Tore Anders, Sodertalje, Sweden
        Ruden, Mats Anders, Askim, Sweden
PA      Astra Aktiebolag, Sodertalje, Sweden (non-U.S. corporation)
PI      US 5772665              19980630
AI      US 1997-970235          19971114 (8)
RLI     Continuation of Ser. No. US 1995-360797, filed on 6 Jan 1995, now
        abandoned
PRAI    SE 1993-3630        19931103
        SE 1994-1010        19940325
DT      Utility
FS      Granted
LN.CNT 580
INCL    INCLM: 604/082.000
        INCLS: 604/085.000; 604/187.000; 604/191.000; 604/213.000; 604/231.000;
               604/236.000; 604/089.000
NCL     NCLM:  604/082.000
        NCLS:  604/085.000; 604/089.000; 604/107.000; 604/191.000; 604/213.000;
               604/231.000; 604/236.000
IC      [6]
        ICM    A61M037-00
        IPCI   A61M0037-00 [ICM,6]
        IPCR   A61M0005-178 [I,C*]; A61M0005-178 [I,A]; A61D0007-00 [I,C*];
               A61D0007-00 [I,A]; A61J0001-00 [N,C*]; A61J0001-00 [N,A];
               A61J0007-00 [I,C*]; A61J0007-00 [I,A]; A61M0003-00 [I,C*];
               A61M0003-00 [I,A]; A61M0005-28 [I,C*]; A61M0005-28 [I,A];
               A61M0005-31 [I,C*]; A61M0005-31 [I,A]; A61M0005-315 [I,C*];
               A61M0005-315 [I,A]
```

EXF 604/82; 604/85; 604/187; 604/191; 604/213; 604/231; 604/236; 604/89

L15 ANSWER 53 OF 58 USPAT2 on STN
Full Text
AN 2007:55439 USPAT2
TI Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof
IN Heese, Gerd-Ulfert, Munich, GERMANY, FEDERAL REPUBLIC OF
Junger, Herbert, Dachau, GERMANY, FEDERAL REPUBLIC OF
Laicher, Arnim, Sauerlach, GERMANY, FEDERAL REPUBLIC OF
Lorck, Claudio, Munich, GERMANY, FEDERAL REPUBLIC OF
Profitlich, Thomas, Munich, GERMANY, FEDERAL REPUBLIC OF
Weiss, Gerd, Munich, GERMANY, FEDERAL REPUBLIC OF
PA AstraZeneca AB, Sodertalje, SWEDEN (non-U.S. corporation)
PI US 7276253 B2 20071002
AI US 2006-502830 20060811 (11)
RLI Division of Ser. No. US 2003-665081, filed on 16 Sep 2003, ABANDONED Continuation of Ser. No. US 2001-947166, filed on 5 Sep 2001, Pat. No. US 6623759 Continuation of Ser. No. US 1998-219985, filed on 23 Dec 1998, ABANDONED Continuation of Ser. No. WO 1997-EP3387, filed on 27 Jun 1997, PENDING
PRAI DE 1996-19626045 19960628
DT Utility
FS GRANTED
LN.CNT 994
INCL INCLM: 424/472.000
INCLS: 424/464.000; 424/471.000; 424/474.000; 424/480.000; 424/489.000; 424/490.000; 424/494.000; 424/472.000
NCL NCLM: 424/472.000
NCLS: 424/464.000; 424/471.000; 424/474.000; 424/480.000; 424/489.000; 424/490.000; 424/494.000; 514/338.000
IC IPCI A61K0009-24 [I,A]; A61K0031-4439 [I,A]; A61K0031-4427 [I,C*]
IPCI-2 A61K0009-14 [I,A]; A61K0009-16 [I,A]; A61K0009-20 [I,A]; A61K0009-24 [I,A]; A61K0009-28 [I,A]
IPCR A61K0009-14 [I,C]; A61K0009-14 [I,A]; A61K0009-16 [I,C]; A61K0009-16 [I,A]; A61K0009-20 [I,C]; A61K0009-20 [I,A]; A61K0009-24 [I,C]; A61K0009-24 [I,A]; A61K0009-28 [I,C]; A61K0009-28 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 54 OF 58 USPAT2 on STN
Full Text
AN 2003:288260 USPAT2
TI Stable oral pharmaceutical dosage forms
IN Chen, Jivn-Ren, Shreveport, LA, UNITED STATES
PA Sage Pharmaceuticals, Inc., Shreveport, LA, UNITED STATES (U.S. corporation)
PI US 7041316 B2 20060509
AI US 2003-422338 20030424 (10)
RLI Division of Ser. No. US 1997-141476, Pat. No. US 6726927 A 371 of International Ser. No. WO 1998-US9449, filed on 8 May 1998 Continuation-in-part of Ser. No. US 1997-950432, filed on 15 Oct 1997, ABANDONED
PRAI US 1997-46089P 19970509 (60)
DT Utility
FS GRANTED
LN.CNT 635
INCL INCLM: 424/463.000
INCLS: 424/451.000; 424/456.000; 424/464.000; 424/474.000; 424/478.000; 424/480.000; 424/482.000; 424/489.000; 514/925.000; 514/962.000
NCL NCLM: 424/463.000; 424/452.000
NCLS: 424/451.000; 424/456.000; 424/464.000; 424/474.000; 424/478.000; 424/480.000; 424/482.000; 424/489.000; 514/925.000; 514/962.000
IC IPCI A61K0009-48 [ICM,7]
IPCI-2 A61L0009-48 [I,A]; A61L0009-64 [I,A]; A61L0009-20 [I,A]; A61L0009-18 [I,C*]; A61L0009-32 [I,A]; A61L0009-14 [I,A]
IPCR A61K0009-30 [I,C]; A61K0009-32 [I,A]; A61K0009-28 [I,C*]; A61K0009-28 [I,A]; A61K0009-48 [I,C]; A61K0009-48 [I,A]; A61K0009-52 [I,C]; A61K0009-64 [I,A]; A61K0031-4164 [I,C*]; A61K0031-4184 [I,A]; A61K0031-4427 [I,C*]; A61K0031-4439 [I,A]; A61L0009-14 [I,C]; A61L0009-18 [I,C]; A61L0009-20 [I,A]
EXF 424/463; 424/451; 424/456; 424/464; 424/474; 424/478; 424/480; 424/482;

424/489; 514/925; 514/962
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 55 OF 58 USPAT2 on STN
Full Text
AN 2003:187448 USPAT2
TI Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
IN Chen, Chih-Ming, Davie, FL, United States
Kositprapa, Unchalee, Davie, FL, United States
PA Andrx Labs LLC, Davie, FL, United States (U.S. corporation)
PI US 6869615 B2 20050322
AI US 2002-282820 20021028 (10)
RLI Continuation of Ser. No. US 2000-659222, filed on 11 Sep 2000, now patented, Pat. No. US 6544556
DT Utility
FS GRANTED
LN.CNT 1196
INCL INCLM: 424/469.000
INCLS: 424/451.000; 424/452.000; 424/457.000; 424/458.000; 424/465.000; 424/468.000; 424/489.000; 424/470.000; 424/474.000; 424/490.000
NCL NCLM: 424/469.000; 424/470.000
NCLS: 424/451.000; 424/452.000; 424/457.000; 424/458.000; 424/465.000; 424/468.000; 424/470.000; 424/474.000; 424/489.000; 424/490.000
IC [7]
ICM A61K009-20
ICS A61K009-22; A61K009-26; A61K009-28; A61K009-54
IPCI A61K0009-26 [ICM,7]
IPCI-2 A61K0009-20 [ICM,7]; A61K0009-22 [ICS,7]; A61K0009-26 [ICS,7]; A61K0009-28 [ICS,7]; A61K0009-54 [ICS,7]; A61K0009-52 [ICS,7,C*]
IPCR A61K0009-22 [I,C*]; A61K0009-22 [I,A]; A61K0009-24 [I,C*]; A61K0009-24 [I,A]; A61K0009-26 [I,C*]; A61K0009-26 [I,A]; A61K0009-28 [N,C*]; A61K0009-28 [N,A]; A61K0009-30 [I,C*]; A61K0009-30 [I,A]; A61K0009-32 [I,A]; A61K0009-34 [I,A]; A61K0009-36 [I,A]; A61K0009-48 [I,C*]; A61K0009-48 [I,A]; A61K0009-50 [N,C*]; A61K0009-50 [N,A]; A61K0009-52 [I,C*]; A61K0009-54 [I,A]; A61K0009-58 [I,A]; A61K0009-60 [I,A]; A61K0009-62 [I,A]; A61K0031-185 [I,C*]; A61K0031-196 [I,A]; A61K0031-415 [I,C*]; A61K0031-415 [I,A]; A61K0031-44 [I,C*]; A61K0031-44 [I,A]; A61K0031-4427 [I,C*]; A61K0031-4439 [I,A]; A61K0045-00 [I,C*]; A61K0045-00 [I,A]; A61K0047-10 [I,C*]; A61K0047-10 [I,A]; A61P0015-00 [I,C*]; A61P0015-00 [I,A]; A61P0019-00 [I,C*]; A61P0019-02 [I,A]; A61P0029-00 [I,C*]; A61P0029-00 [I,A]; A61P0043-00 [I,C*]; A61P0043-00 [I,A]
EXF 424/489; 424/490; 424/469; 424/451; 424/452; 424/457; 424/458; 424/464; 424/465; 424/470; 424/472; 424/468; 424/474; 424/484; 424/455; 424/456; 424/480; 424/481; 424/482; 424/493; 424/494; 424/495; 424/497; 424/496; 424/477
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 56 OF 58 USPAT2 on STN
Full Text
AN 2002:279721 USPAT2
TI Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a NSAID
IN Depui, Helene, Goteborg, SWEDEN
Lundberg, Per, Molndal, SWEDEN
PA AstraZeneca AB, Sodertalje, SWEDEN (non-U.S. corporation)
PI US 6613354 B2 20030902
AI US 2002-90882 20020304 (10)
RLI Continuation of Ser. No. US 1999-471958, filed on 23 Dec 1999, now patented, Pat. No. US 6365184 Continuation of Ser. No. US 793078, now abandoned
DT Utility
FS GRANTED
LN.CNT 1287
INCL INCLM: 424/458.000
INCLS: 424/451.000; 424/452.000; 424/457.000
NCL NCLM: 424/458.000; 424/452.000
NCLS: 424/451.000; 424/452.000; 424/457.000; 424/465.000; 514/338.000
IC [7]
ICM A61K009-48

```
       ICS    A61K009-52; A61K009-54
       IPCI   A61K0031-4439 [ICM,7]; A61K0031-4427 [ICM,7,C*]; A61K0009-48
              [ICS,7]; A61K0009-20 [ICS,7]
       IPCI-2 A61K0009-48 [ICM,7]; A61K0009-52 [ICS,7]; A61K0009-54 [ICS,7];
              A61K0009-52 [ICS,7,C*]
       IPCR   A61K0009-20 [I,C*]; A61K0009-20 [I,A]; A61K0009-24 [I,C*];
              A61K0009-24 [I,A]; A61K0009-28 [I,C*]; A61K0009-28 [I,A];
              A61K0009-50 [I,C*]; A61K0009-50 [I,A]; A61K0009-52 [I,C*];
              A61K0009-52 [I,A]; A61K0009-54 [I,A]; A61K0045-00 [I,C*];
              A61K0045-06 [I,A]
EXF    424/468; 424/465; 424/474; 424/489; 424/490; 424/469; 424/464; 424/470;
       424/471; 424/493; 424/494; 424/458; 424/457; 424/452; 424/451; 424/459;
       424/461; 424/462
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15  ANSWER 57 OF 58  USPAT2 on STN
Full Text
AN     2002:105711  USPAT2
TI     Stable drug form for oral administration with benzimidazole derivatives
       as active ingredient and process for the preparation thereof
IN     Heese, Gerd-Ulfert, Munich, GERMANY, FEDERAL REPUBLIC OF
       Junger, Herbert, Dachau, GERMANY, FEDERAL REPUBLIC OF
       Laicher, Arnim, Sauerlach, GERMANY, FEDERAL REPUBLIC OF
       Lorck, Claudio, Munich, GERMANY, FEDERAL REPUBLIC OF
       Profitlich, Thomas, Munich, GERMANY, FEDERAL REPUBLIC OF
       Weiss, Gerd, Munich, GERMANY, FEDERAL REPUBLIC OF
PA     AstraZeneca AB, Sodertalje, SWEDEN (non-U.S. corporation)
PI     US 6623759          B2  20030923
AI     US 2001-947166          20010905 (9)
RLI    Continuation of Ser. No. US 1998-219985, filed on 23 Dec 1998, now
       abandoned
PRAI   DE 1996-19626045    19960628
DT     Utility
FS     GRANTED
LN.CNT 950
INCL   INCLM: 424/480.000
       INCLS: 424/472.000; 424/475.000; 424/482.000; 424/490.000; 424/494.000;
              424/497.000; 424/461.000; 424/462.000; 514/772.300; 514/781.000
NCL    NCLM:  424/480.000; 424/490.000
       NCLS:  424/461.000; 424/462.000; 424/472.000; 424/475.000; 424/482.000;
              424/490.000; 424/494.000; 424/497.000; 514/772.300; 514/781.000
IC     [7]
       ICM    A61K009-24
       ICS    A61K009-32; A61K009-36; A61K009-58; A61K009-62
       IPCI   A61K0009-16 [ICM,7]; A61K0009-50 [ICS,7]
       IPCI-2 A61K0009-24 [ICM,7]; A61K0009-32 [ICS,7]; A61K0009-36 [ICS,7];
              A61K0009-30 [ICS,7,C*]; A61K0009-58 [ICS,7]; A61K0009-62 [ICS,7];
              A61K0009-52 [ICS,7,C*]
       IPCR   A61K0009-30 [I,C*]; A61K0009-32 [I,A]; A61K0009-36 [I,A];
              A61K0009-50 [I,C*]; A61K0009-50 [I,A]; A61K0009-52 [I,C*];
              A61K0009-58 [I,A]; A61K0009-62 [I,A]; A61K0031-4427 [I,C*];
              A61K0031-4439 [I,A]
EXF    424/461; 424/462; 424/494; 424/497; 424/459; 424/468; 424/476; 424/480;
       424/482; 424/490; 424/475
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15  ANSWER 58 OF 58  USPAT2 on STN
Full Text
AN     2002:85601  USPAT2
TI     Substituted benzimidazole dosage forms and method of using same
IN     Phillips, Jeffrey O., Ashland, MO, United States
PA     Curators of the University of Missouri, Columbia, MO, United States
       (U.S. corporation)
PI     US 6645988          B2  20031111
AI     US 2001-901942          20010709 (9)
RLI    Continuation-in-part of Ser. No. US 2000-481207, filed on 11 Jan 2000,
       now patented, Pat. No. US 6489346 Continuation-in-part of Ser. No. US
       1998-183422, filed on 30 Oct 1998, now abandoned Continuation-in-part of
       Ser. No. US 1996-680376, filed on 15 Jul 1996, now patented, Pat. No. US
       5840737
PRAI   US 1996-9608P       19960104 (60)
DT     Utility
```

```
FS      GRANTED
LN.CNT 4173
INCL    INCLM: 514/338.000
        INCLS: 546/273.700; 548/307.100; 514/395.000
NCL     NCLM:  514/338.000
        NCLS:  514/395.000; 546/273.700; 548/307.100
IC      [7]
        ICM    A61K031-4439
        IPCI   A61K0031-4439 [ICM,7]; A61K0031-4427 [ICM,7,C*]
        IPCI-2 A61K0031-4439 [ICM,7]; A61K0031-4427 [ICM,7,C*]
        IPCR   A61K0009-00 [I,C*]; A61K0009-00 [I,A]; A61K0009-20 [I,C*];
               A61K0009-20 [I,A]; A61K0009-24 [I,C*]; A61K0009-24 [I,A];
               A61K0009-28 [I,C*]; A61K0009-28 [I,A]; A61K0009-46 [I,C*];
               A61K0009-46 [I,A]; A61K0031-00 [I,C*]; A61K0031-00 [I,A];
               A61K0031-185 [I,C*]; A61K0031-198 [I,A]; A61K0031-4427 [I,C*];
               A61K0031-4439 [I,A]; A61K0031-519 [I,C*]; A61K0031-522 [I,A];
               A61K0033-00 [I,C*]; A61K0033-00 [I,A]; A61K0033-06 [I,C*];
               A61K0033-06 [I,A]; A61K0036-00 [I,C*]; A61K0036-00 [I,A];
               A61K0036-185 [I,C*]; A61K0036-534 [I,A]; A61K0036-82 [I,A];
               A61K0045-00 [I,C*]; A61K0045-06 [I,A]; A61K0047-02 [I,C*];
               A61K0047-02 [I,A]
EXF     514/338
CAS INDEXING IS AVAILABLE FOR THIS PATENT.


=> d pi kwic 50-58

L15  ANSWER 50 OF 58  USPATFULL on STN
Full Text
PI      US 6136344              20001024
        WO 9624375  19960815
CLM     What is claimed is:
 . . .  consisting essentially of, as a first component, at least one
        antibacterial compound, and as a second component, an acid susceptible
        proton pump inhibitor, wherein: (a) the composition is in the form
        of a multiple unit tablet; (b) the proton pump inhibitor is in the
        form of pellets covered with an enteric coating polymer layer; (c) the
        first component is separated from the proton pump inhibitor by the
        enteric coating layer covering the second component; and (d) the
        enteric coating layer has mechanical properties such that the acid
        resistance of the enteric coated pellets is not significantly affected
        by compression of.  .  .
        4. The composition according to claim 1, wherein the antibacterial
        component in the form of granules of the antibacterial component.

        5. The composition of claim 1, wherein the proton pump inhibitor
        is omeprazole or a pharmaceutically acceptable salt of omeprazole.

        6. The composition of claim 1, wherein the proton pump inhibitor
        is omeprazole, an alkaline salt of omeprazole, a (-)-enantiomer of
        omeprazole or an alkaline salt of the (-)-enantiomer of omeprazole.
        .  .  .
        7. The composition of claim 1, wherein the proton pump inhibitor
        is S-omeprazole magnesium salt.

        8. The composition of claim 1, wherein the proton pump inhibitor
        is lansoprazole, a pharmaceutically acceptable salt of lansoprazole,
        a single enantiomer of lansoprazole or a pharmaceutically acceptable
        salt of the enantiomer of lansoprazole.

        11. The composition of claim 1, wherein the amount of the antibacterial
        component is in the range of 100-900 mg and the amount of the proton
        pump inhibitor is in the range of 10-80 mg.

 .  .  .  wherein the amount of the first antibacterial component is in the
        range of 250-650 mg and the amount of the proton pump inhibitor is
        in the range of 20-40 mg.

        13. The composition of claim 1, wherein the tablet is in the form of two
        separate layers.

        14. The composition of claim 13, wherein the acid susceptible proton
```

pump inhibitor is located in one **layer** and wherein the antibacterial component is located in the other **layer.**

15. The composition of claim 1, wherein the acid resistance of the enteric coating **layered** pellets is in compliance with the requirements on enteric coating **layered** articles as defined in the United States Pharmacopeia and does not decrease more than 10% upon tableting of the pellets. . .
16. The composition of claim 1, wherein the **proton pump inhibitor** is covered by a separating **layer** located underneath the enteric coating **layer.**

17. The composition of claim 1, wherein the enteric coating **layer** of the pellet comprises more than one **layer.**

18. The composition of claim 1, wherein the enteric coating **layer** of the pellet comprises a plasticized enteric coating **layer** material.

19. The composition of claim 1, wherein the enteric coating **layered** pellets are further covered with an over-coating **layer** comprising a pharmaceutically acceptable excipient.

22. The composition of claim 20, wherein the tablet is dispersible to a suspension of individually enteric coating **layered** pellets in an aqueous liquid.

23. The composition of claim 18, wherein the amount of plasticizer is 20-50% by weight of the enteric coating **layer** polymer.

. . . consisting essentially of, as a first component, at least one antibacterial compound, and as a second component, an acid susceptible **proton pump inhibitor**, wherein the process comprises the steps of: (a) preparing the **proton pump inhibitor** in the form of enteric coating **layered** pellets; (b) mixing the enteric coated pellets with a prepared **granules** of the antibacterial component; (c) drying the mixture; and (d) compressing the mixture into a multiple unit tablet without affecting any significant change of the acid resistance of the enteric coating **layered** pellets.

L15 ANSWER 51 OF 58 USPATFULL on STN
Full Text
PI US 5824339 19981020
CLM What is claimed is:
1. An effervescent composition which comprises (a) a core-shell powder which comprises a fine **granular** core having a specific volume not exceeding about 5 ml/g coated with a **layer** comprising a water-soluble polymer and an effective amount of an acid-sensitive physiologically active substance and an enteric coating **layer**, wherein the average particle diameters of the core-shell powder do not exceed about 300 μm; (b) an effervescing component; and. . .
2. The effervescent composition as claimed in claim 1, wherein said fine **granular** core is physiologically inactive.

3. The effervescent composition as claimed in claim 1, wherein said fine **granular** core is spherical.

7. The effervescent composition as claimed in claim 6, wherein said benzimidazole derivative is **lansoprazole.**

8. The effervescent composition as claimed in claim 1, wherein the proportion of said enteric coating **layer** is about 35 to about 50% by weight of the core-shell powder.

. . . The effervescent composition as claimed in claim 1, which comprises (a) a core-shell powder which comprises a physiologically inactive fine **granular** core coated with a **layer** comprising a water-soluble cellulose derivative and an effective amount of **lansoprazole** and an enteric coating **layer**; (b) an effervescing component selected from alkali metal carbonates; and (c) an auxiliary effervescing agent selected from edible hydroxy-carboxylic acids;. . .
13. A method of producing an effervescing composition which comprises

mixing (a) a core-shell powder which comprises a fine **granular** core having specific volume not exceeding about 5 ml/g coated with a **layer** comprising a water-soluble polymer and an effective amount of acid-sensitive physiologically active substance and an enteric-coating **layer**, wherein the average particle diameters of the core-shell powder do not exceed about 300 μm; with (b) an effervescing component;. . .

. . . suspension of an acid-sensitive physiologically active substance for oral administration which comprises (a) a core-shell powder which comprises a fine **granular** core having a specific volume not exceeding 5 ml/g coated with a **layer** comprising a water-soluble polymer and an effective amount of acid-sensitive physiologically active substance and an enteric-coating **layer**, wherein the average particle diameters of the core-shell powder to not exceeding about 300 μm; (b) an effervescing component; and. . .

L15 ANSWER 52 OF 58 USPATFULL on STN
Full Text
PI US 5772665 19980630
CLM What is claimed is:
11. A syringe according to claim 10, wherein said at least one moisture barrier is comprised by an aluminium **layer**.

12. A syringe according to any of claims 1-2, wherein said pharmaceutical composition is constituted by enteric coated pellets of a **proton pump inhibitor** such as omeprazole pellets mixed with a dry gelforming agent.

13. A process for preparing a pharmaceutical preparation by mixing a pharmaceutical, preferably dry and **granular**, composition with a, preferably fluid, agent shortly before the administration thereof to a living being, comprising the following steps: filling. . .
14. A method for oral administration of a pharmaceutical preparation, which is achieved by mixing a preferably dry and **granular**, composition with a preferably fluid agent, said composition being contained in the chamber of the syringe according to claims 1. . .

L15 ANSWER 53 OF 58 USPAT2 on STN
Full Text
PI US 7276253 B2 20071002
CLM What is claimed is:
. . . for oral administration which comprises: (a) a core which contains an active ingredient selected from the group consisting of Omeprazole, **Lansoprazole**, and **Pantoprazole**, together with pharmaceutical adjuvants; (b) an intermediate **layer** applied onto the core; and (c) a gastric juice-resistant outer **layer**, wherein the intermediate **layer** is a reactive **layer** comprising a gastric juice-resistant polymeric **layered** material partially neutralized with alkali and having cation exchange capacity.
. . according to claim 1, wherein the core is present in the form of pellet cores, tablets, microtablets, or as a **granulate**.

7. The method according to claim 1, wherein the polymeric **layered** material is partially neutralized to a pH range of about 5.5 to about 7.0.

8. The method according to claim 7, wherein the polymeric **layered** material is selected from the group consisting of a partially neutralized copolymer of methacrylic acid and ethylacrylate, a copolymer of. . .
9. The method according to claim 1, wherein the intermediate **layer** further comprises a plasticizer.

11. The method according to claim 1, wherein the intermediate **layer** forms a gel **layer** with penetration of protons through the outer **layer**.

12. The method according to claim 1, wherein the intermediate **layer** possesses a thickness of from about 5 to about 30 μm.

13. The method according to any one of claims 1 to 12, wherein the gastric juice-resistant outer **layer** in (c) contains a copolymer selected from the group consisting of copolymers of methacrylic acid and

ethylacrylate, copolymers of methacrylic. . .
14. The method according to claim 13, wherein the gastric juice-resistant outer **layer** contains compounds selected from the group consisting of pharmaceutically acceptable antitacking agents, dispersion agents, pigments and colorants.

16. The method according to claim 1, wherein the gastric juice-resistant outer **layer** has a **layer** of thickness from about 20 to about 60 μm.

. . . medicament for oral administration comprises: (a) a core which contains an active ingredient selected from the group consisting of Omeprazole, **Lansoprazole**, and **Pantoprazole**, together with mannite and hydroxypropylcellulose as adjuvants without alkaline additives; (b) a reactive intermediate **layer** applied on the core with a thickness from about 5 to about 30 μm of a copolymer of methacrylic acid. . . neutralized with sodium hydroxide to a pH range of about 5.5 to about 7.0; and (c) a gastric juice-resistant outer **layer** of a copolymer of methacrylic acid and ethylacrylate with a thickness from about 30 to about 60 μm.

18. The method according to claim 1, wherein the intermediate **layer** is formed as a plurality of single **layers**.

19. The method according to claim 1, wherein the gastric juice-resistant outer **layer** is formed as a plurality of single **layers**.

20. The method according to claim 1, wherein the pH transition at the border of the gastric juice-resistant outer **layer** to the reactive intermediate **layer** is formed as a gradient.

. . . the Diclofenac is present as a formulation which comprises: (a) a Diclofenac-containing core together with adjuvants; (b) a reactive intermediate **layer** of gastric juice-resistant polymeric **layered** material partially neutralized with alkali; and (c) a gastric juice-resistant outer **layer**.

L15 ANSWER 54 OF 58 USPAT2 on STN
Full Text
PI US 7041316 B2 20060509
CLM What is claimed is:
. . . A pharmaceutical dosage form for oral administration to human being or animal host which consists essentially of: (a) a core **granulation** formed by dry mixing, without using an aqueous **granulation** solution, an acid-unstable drug with an alkaline substance and a pharmaceutical excipient or excipients, wherein the core **granulation** is capable of being quantitatively filled into an empty hard gelatin capsule shell having an outer surface and an inner surface, wherein the hard gelatine capsule shell separates the core **granulation** from an enteric coating, and wherein the acid-unstable drug is omeprazole, sodium omeprazole, potassium omeprazole, **lansoprazole**, or a pharmaceutical salt of **lansoprazole**; and (b) the enteric coating being disposed on the outer surface of the hard gelatin capsule shell to prevent the. . .
. . . shell separates the core tablet from an enteric coating, and wherein the acid-unstable drug is omeprazole, sodium omeprazole, potassium omeprazole, **lansoprazole**, or a pharmaceutical salt of **lansoprazole**; and (b) the enteric coating being disposed on the outer surface of the hard gelatin capsule shell to protect the. . .
. . . and then by direct compression, wherein the acid-unstable drug is omeprazole, sodium omeprazole, potassium omeprazole, or a pharmaceutical salt of **lansoprazole**, and wherein the core tablet is subcoated with a protective **layer** as a barrier to: (i) separate the acid-unstable active drug in the core tablet from an enteric coating; and (ii). . .
. . . is selected from one or any combination of the group consisting of alkaline metallic salt of carbonic acid, calcium carbonate, **granulated** calcium carbonate, dicalcium phosphate anhydrous, dibasic sodium phosphate anhydrous, tricalcium phosphate anhydrous, sodium carboxymethylcellulose, calcium carboxymethylcellulose, magnesium aluminum silicate, sodium. . .
7. The pharmaceutical dosage form according to claim 3 wherein the protective **layer** comprises: (a) non-ionic protective polymer selected from the group consisting of hydroxypropyl methylcellulose, hydroxyethyl

cellulose, and hydroxypropyl cellulose polyvinylpyrolidone; (b). . . . . (a) a core formulation comprising an acid-unstable drug and an alkaline substance, formed by dry mixing without using an aqueous **granulating** solution, wherein the acid-unstable drug is omeprazole, sodium omeprazole, potassium omeprazole, **lansoprazole**, or a pharmaceutical salt of **lansoprazole**; (b) a hard gelatin capsule shell housing the core formulation, wherein the gelatin capsule shell has an outer surface and. . .
11. The oral pharmaceutical preparation of claim 8, wherein the core formulation is in the form of powder or **granules**.

13. The pharmaceutical dosage form according to claim 8 wherein the alkaline substance is selected from one or any combination of the group consisting of alkaline metallic salt of carbonic acid, calcium carbonate, **granulated** calcium carbonate, dicalcium phosphate anhydrous, dibasic sodium phosphate anhydrous, tricalcium phosphate anhydrous, sodium carboxymethylcellulose, calcium carboxymethylcellulose, magnesium aluminum silicate, sodium. . .

L15 ANSWER 55 OF 58 USPAT2 on STN
Full Text
PI US 6869615 B2 20050322
CLM What is claimed is:
1. A solid oral dosage form comprising a) a population of substrates comprising a **proton-pump inhibitor**; b) an enteric coating **layer** coated over said substrates; and c) an NSAID coating **layer** coated over said enteric coated substrates.

4. The solid dosage form of claim 1 wherein said **proton pump inhibitor** is selected from the group consisting of omeprazole, **lansoprazole**, rabeprazole, **pantoprazole**, **leminoprazole**, single enantiomers thereof, alkaline salts thereof and mixtures thereof.

5. The solid dosage form of claim 1 wherein said **proton pump inhibitor** is omeprazole or a pharmaceutically acceptable salt thereof.

6. The solid dosage form of claim 1 wherein said substrates are a plurality of inert beads and said **proton-pump inhibitor** is coated onto said beads.

8. The solid dosage form of claim 7 wherein said **proton pump inhibitor** is selected from the group consisting of omeprazole, **lansoprazole**, rabeprazole, **pantoprazole**, **leminoprazole**, single enantiomers thereof, alkaline salts thereof and mixtures thereof.

9. The solid dosage form of claim 8 wherein said **proton pump inhibitor** is omeprazole or a pharmaceutically acceptable salt thereof.

10. A solid dosage form for oral administration comprising a compressed matrix comprising an NSAID and a **proton-pump inhibitor**, and a retardant material in an effective amount to provide a controlled release of said NSAID and said **proton-pump inhibitor** sufficient to provide a therapeutic effect for at least about 24 hours; and said compressed matrix overcoated with a material suitable to prevent contact of said **proton pump inhibitor** with acidic gastric juice after oral administration.

11. The solid dosage form of claim 10 wherein said **proton pump inhibitor** is selected from the group consisting of omeprazole, **lansoprazole**, rabeprazole, **pantoprazole**, **leminoprazole**, single enantiomers thereof, alkaline salts thereof and mixtures thereof.

12. The solid dosage form of claim 11 wherein said **proton pump inhibitor** is omeprazole or an alkaline salt thereof.

13. The solid dosage form of claim 10, wherein said **proton pump inhibitor** is in an amount effective to inhibit gastrointestinal side effects associated with oral administration of said NSAID or pharmaceutically acceptable. . .
14. The solid dosage form of claim 10 wherein said material suitable to prevent contact of said **proton pump inhibitor** with acidic gastric juice is an enteric coating.

18. The solid dosage form of claim 10 wherein said NSAID, said **proton-pump inhibitor** and said retardant material are in **granular** form prior to compression.

. . . material in an effective amount to provide a controlled release of said NSAID; and a plurality of particles comprising a **proton pump inhibitor** coated onto the surface of a plurality of inert beads and overcoated with a material suitable to prevent contact of said **proton pump inhibitor** with acidic gastric juice after oral administration; paid dosage form containing a sufficient amount of said particles to provide an effective dose of said **proton pump inhibitor** to inhibit gastrointestinal side effects associated with oral administration of said NSAID; said compressed matrix and said dose of **proton pump inhibitor** contained within a capsule.

21. The oral solid dosage form of claim 20, wherein said **proton-pump inhibitor** is selected from the group consisting of omeprazole, **lansoprazole,** rabeprazole, **pantoprazole, leminoprazole,** single enantiomers thereof, alkaline salts thereof and mixtures thereof.

22. The solid oral dosage form of claim 1, wherein the **proton-pump inhibitor** is in a therapeutically effective amount.

23. The solid oral dosage form of claim 1, wherein the **proton-pump inhibitor** is in an amount effective to inhibit gastrointestinal side effects associated with oral administration of said diclofenac or pharmaceutically acceptable. . .

L15 ANSWER 56 OF 58 USPAT2 on STN
Full Text
PI US 6613354 B2 20030902
CLM What is claimed is:
1. A capsule formulation comprising an acid susceptible **proton pump inhibitor,** one or more Non Steroidal Antiinflammatory Drugs (NSAID(s)), an enteric coating **layer** to protect the **proton pump inhibitor** and, optionally, pharmaceutically acceptable excipients.

2. The capsule formulation according to claim 1, wherein the **proton pump inhibitor** is in the form of pellets covered with an enteric coating **layer.**

3. The capsule formulation according to claim 1, further comprising a separating **layer** located underneath the enteric coating **layer.**

4. The capsule formulation according to claim 1, wherein the dosage form comprises the **proton pump inhibitor** and one NSAID.

5. The capsule formulation according to claim 1, wherein the **proton pump inhibitor** is omeprazole, an alkaline salt of omeprazole, a single enantiomer of omeprazole or an alkaline salt of the single enantiomer.
. . .
6. The capsule formulation according to claim 5, wherein the **proton pump inhibitor** is S-omeprazole magnesium salt.

7. The capsule formulation according to claim 1, wherein the **proton pump inhibitor** is **lansoprazole,** a pharmaceutically acceptable salt of **lansoprazole,** a single enantiomer of **lansoprazole** or a pharmaceutically acceptable salt of the single enantiomer.
8. The capsule formulation according to claim 1, wherein the **proton pump inhibitor** is **pantoprazole,** a pharmaceutically acceptable salt of **pantoprazole,** a single enantiomer of **pantoprazole** or a pharmaceutically acceptable salt of the single enantiomer.
11. The capsule formulation according to claim 1, wherein the amount of the **proton pump inhibitor** is in the range of 10-80 mg and the amount of NSAID(s) is in the range of 10-800 mg.

12. The capsule formulation according to claim 1, wherein the amount of the **proton pump inhibitor** is in the range of 10-40 mg and the amount of NSAID(s) is in the range of 10-500 mg.

13. The capsule formulation according to claim 2, wherein the acid resistance of the enteric coating **layered** pellets is in compliance with the requirements on enteric coating **layered** articles defined in the United States Pharmacopeia.

14. The capsule formulation according to claim 2, wherein the acid resistance of the enteric coating **layered** pellets does not decrease more than 10% in compliance with the requirements on enteric coating **layered** articles defined in the United States Pharmacopeia.

16. The capsule formulation according to claim 2, wherein the enteric coating **layered** pellets are further covered with an over-coating **layer** comprising pharmaceutically acceptable excipients.

17. The capsule formulation according to claim 1, wherein the **proton pump inhibitor** is in the form of pellets covered with an enteric coating **layer,** and wherein the NSAID(s), is in the form of pellets covered with an enteric coating **layer.**

18. The capsule formulation according to claim 1, wherein the **proton pump inhibitor** is in the form of pellets covered with an enteric coating **layer,** and wherein the NSAID(s) is in the form of pellets coating **layered** with an extended release film.

19. A process for the manufacture of a capsule formulation comprising a **proton pump inhibitor** and one or more Non Steroidal Antiinflammatory Drugs (NSAID(s)), wherein the process comprises the steps: (a) preparing the **proton pump inhibitor** in the form of enteric coating **layered** pellets, and (b) filling a capsule with the pellets, the NSAID(s) selected from the group consisting of prepared NSAID **granules,** enteric coating **layered** NSAID pellets, and NSAID pellets coating **layered** with an extended release film, and optionally, pharmaceutically acceptable excipients.

L15 ANSWER 57 OF 58 USPAT2 on STN
Full Text
PI US 6623759 B2 20030923
CLM What is claimed is:
. . . for oral administration which comprises: (a) a core which contains an active ingredient selected from the group consisting of Omeprazole, **Lansoprazole,** and **Pantoprazole,** together with pharmaceutical adjuvants; (b) an intermediate **layer** applied onto the core; and (c) a gastric juice-resistant outer **layer,** wherein the intermediate **layer** is a reactive **layer** comprising a gastric juice-resistant polymeric **layered** material partially neutralized with alkali and having cation exchange capacity.
. . . according to claim 1, wherein the core is present in the form of pellet cores, tablets, microtablets, or as a **granulate.**

7. The medicament according to claim 1, wherein the polymeric **layered** material is partially neutralized to a pH range of about 5.5 to about 7.0.

8. The medicament according to claim 7, wherein the polymeric **layered** material is selected from the group consisting of a partially neutralized copolymer of methacrylic acid and ethylacrylate, a copolymer of. . .
9. The medicament according to claim 1, wherein the intermediate **layer** further comprises a plasticizer.

11. The medicament according to claim 1, wherein the intermediate **layer** forms a gel **layer** with penetration of protons through the outer **layer.**

12. The medicament according to claim 1, wherein the intermediate **layer** possesses a thickness of from about 5 to about 30 μm.

13. The medicament according to any one of claims 1 to 12, wherein the gastric juice-resistant outer **layer** in (c) contains a copolymer selected from the group consisting of copolymers of methacrylic acid and ethylacrylate, copolymers of methacrylic. . .
14. The medicament according to claim 13, wherein the gastric

juice-resistant outer **layer** contains compounds selected from the group consisting of pharmaceutically acceptable antitacking agents, dispersion agents, pigments, and colorants.

16. The medicament according to claim 1, wherein the gastric juice-resistant outer **layer** has a **layer** of thickness from about 20 to about 60 µm.

. . . according to claim 1 comprising: (a) a core which contains an active ingredient selected from the group consisting of Omeprazole, **Lansoprazole**, and **Pantoprazole**, together with mannite and hydroxypropylcellulose as adjuvants without alkaline additives; (b) a reactive intermediate **layer** applied on the core with a thickness from about 5 to about 30 µm of a copolymer of methacrylic acid. . . . neutralized with sodium hydroxide to a pH range of about 5.5 to about 7.0; and (c) a gastric juice-resistant outer **layer** of a copolymer of methacrylic acid and ethylacrylate with a thickness from about 30 to about 60 µm.

18. The medicament according to claim 1, wherein the intermediate **layer** is formed as a plurality of single **layers**.

19. The medicament according to claim 1, wherein the gastric juice-resistant outer **layer** is formed as a plurality of single **layers**.

20. The medicament according to claim 1, wherein the pH transition at the border of the gastric juice-resistant outer **layer** to the reactive intermediate **layer** is formed as a gradient.

. . . (a) forming a molded article as a core which contains an active ingredient selected from the group consisting of Omeprazole, **Lansoprazole**, and **Pantoprazole**, together with pharmaceutical adjuvants; (b) applying an intermediate **layer** onto the molded article; and (c) applying onto the intermediate **layer** a gastric juice-resistant **layer**, wherein the intermediate **layer** is a reactive **layer** comprising a gastric juice-resistant polymeric **layered** material partially neutralized with alkali and having cation exchange capacity. 22. The method according to claim 21, wherein the gastric juice-resistant polymeric **layered** material is partially neutralized with alkali to a pH range of from about 5.5 to about 7.0 before spraying.

. . . the Diclofenac is present as a formulation which comprises: (a) a Diclofenac-containing core together with adjuvants; (b) a reactive intermediate **layer** of gastric juice-resistant polymeric **layered** material partially neutralized with alkali; and (c) a gastric juice-resistant outer **layer**.

29. The medicament according to claim 7, wherein the gastric juice-resistant polymeric **layered** material is partially neutralized to a pH range of about 5.5 to about 6.5

30. The medicament according to claim 16, wherein the gastric juice-resistant outer **layer** has a **layer** thickness of from about 30 to 60 µm.

L15 ANSWER 58 OF 58 USPAT2 on STN
Full Text
PI US 6645988 B2 20031111
CLM What is claimed is:
. . . A solid oral pharmaceutical dosage form that is not enteric-coated, comprising: active ingredients consisting essentially of: (a) at least one **proton pump inhibitor** (PPI) selected from the group consisting of omeprazole, **lansoprazole**, rabeprazole, esomeprazole, **pantoprazole**, **pariprazole**, and **leminoprazole**, and an enantiomer, isomer, free base, or salt thereof, in an amount of approximately 5 mg to approximately 300 mg;. . . one optional Secondary Essential Buffer in a total amount of approximately 0.1 mEq to approximately 2.5 mEq per mg of **proton pump inhibitor**; and a pharmaceutically-acceptable excipient; wherein the dosage form is selected from the group consisting of a suspension tablet, chewable tablet,. . .

2. The dosage form of claim 1, wherein the **proton pump inhibitor** is in an amount from approximately 10 mg to approximately 100 mg.

3. The dosage form of claim 1, wherein the **proton pump inhibitor** is omeprazole.

4. The dosage form of claim 1, wherein the **proton pump inhibitor** is **lansoprazole.**

5. The dosage form of claim 1, wherein the **proton pump inhibitor** is **pantoprazole**.

6. The dosage form of claim 1, wherein the **proton pump inhibitor** is rabeprazole.

7. The dosage form of claim 1, wherein the **proton pump inhibitor** is esomeprazole.

8. The dosage form of claim 1, wherein the **proton pump inhibitor** is **pariprazole.**

9. The dosage form of claim 1, wherein the **proton pump inhibitor** is **leminoprazole.**

24. A solid oral pharmaceutical dosage form that is not enteric-coated, comprising: an outer **layer** and an inner core; the outer **layer** comprising active ingredients consisting essentially of at least one Primary Essential Buffer; and the inner core comprising active ingredients consisting essentially of at least one **proton pump inhibitor** selected from the group consisting of omeprazole, **lansoprazole**, rabeprazole, esomeprazole, **pantoprazole, pariprazole**, and **leminoprazole**, or an enantiomer, isomer, free base, or salt thereof, and at least one buffering agent selected from the group consisting of a Primary Essential Buffer and a Secondary Essential Buffer; wherein the total amount of the **proton pump inhibitor** is approximately 5 mg to approximately 300 mg; and the total amount of the buffering agent is approximately 0.1 mEq to approximately 2.5 mEq per mg of **proton pump inhibitor.**

. . . effective to elevate pH of gastric fluid of the subject upon oral administration to at least 3.7 from time the **proton pump inhibitor** comes in contact with the gastric fluid throughout dwell time in the stomach.

29. A non-enteric coated solid oral pharmaceutical dosage form, comprising: (a) active ingredients consisting essentially of: (i) a **proton pump inhibitor** (PPI) selected from the group consisting of omeprazole, **lansoprazole**, rabeprazole, esomeprazole, **pantoprazole, pariprazole**, and **leminoprazole**, and an enantiomer, isomer, free base, and salt thereof, in an amount of approximately 5 mg to approximately 300 mg;. . . one optional Secondary Essential Buffer in a total amount of approximately 0.1 mEq to approximately 2.5 mEq per mg of **proton pump inhibitor;** and (b) a pharmaceutically-acceptable excipient; wherein the dosage form is created by a method comprising: i) blending the **proton pump inhibitor,** the Primary Essential Buffer, the optional Secondary Essential Buffer, and the pharmaceutically-acceptable excipient; and ii) formulating the **proton pump inhibitor**, the Primary Essential Buffer, the optional Secondary Essential Buffer, and the pharmaceutically-acceptable excipient into a powder, tablet, suspension tablet, chewable tablet, capsule, two-part tablet, two-part capsule, effervescent powder, pellet, **granule** or effervescent tablet.

=> d pi kwic 46 48 51

L15 ANSWER 46 OF 58 USPATFULL on STN
Full Text
PI US 6328994 B1 20011211
WO 9959544 19991125
CLM What is claimed is:

1. An orally disintegrable tablet which comprises (i) fine **granules** having an average particle diameter of 400 μm or less, which fine **granules** comprise a composition coated by an enteric coating **layer** comprising a first component which is an enteric coating agent and a second component which is a sustained-release agent, said composition having 10 weight % or more of an acid-labile physiologically active substrate that is **lansoprazole** and (ii) an additive wherein said tablet having a hardness strength of about 1 to about 20 kg, is orally. . .

2. An orally disintegrable tablet of claim 1, wherein the average particle diameter of the fine **granule** is 300 to 400 μm.

3. An orally disintegrable tablet of claim 1, wherein the fine **granules** further comprise a basic inorganic salt.

5. An orally disintegrable tablet of claim 1, wherein the composition coated by an enteric coating **layer** is further coated by a coating **layer** which comprises a water-soluble sugar alcohol.

7. An orally disintegrable tablet of claim 1, wherein the particle diameter of the fine **granules** is practically 425 μm or less.

8. An orally disintegrable tablet of claim 1, wherein the particle diameter of the fine **granules** is practically 400 μm or less.

15. An orally disintegrable tablet of claim 1, wherein the fine **granules** are produced by fluidized-bed **granulation** method.

16. An orally disintegrable tablet of claim 1, wherein the enteric coating **layer** comprises an aqueous enteric polymer agent.

. . . of 5 to 97 weight % relative to 100 weight % of the orally disintegrable tablet apart from the fine **granules**.

. . . an amount of 3 to 50 weight % relative to 100 weight % of the tablet apart from the fine **granule**.

29. Fine **granules** having an average particle diameter of 400 μm or less, which comprise a composition coated by an enteric coating **layer** comprising a first component which is an enteric coating agent and a second component which is a sustained-release agent, said composition having (i) 25 weight % or more of an acid-liable physiologically active substance that is **lansoprazole** and (ii) a basic inorganic salt.

30. Fine **granules** of claim 28, wherein the average particle diameter of the fine **granules** is 300 to 400 μm.

31. Fine **granules** of claim 28, wherein the particle diameter of the fine **granules** is practically 425 μm or less.

32. Fine **granules** of claim 28, wherein the particle diameter of the fine **granules** is practically 400 μm or less.

33. Fine **granules** of claim 28, wherein the basic inorganic salt is a salt of magnesium and/or a salt of calcium.

34. Fine **granules** of claim 28, wherein the composition comprises a core being coated by a benzimidazole compound and a basic inorganic salt,. . .

35. Fine **granules** of claim 34, wherein the core comprises 50 weight % or more of lactose.

36. Fine **granules** of claim 28, wherein the composition comprises 25 to 40 weight % of an acid-labile physiologically active substance.

37. Fine **granules** of claim 28, which are produced by fluidized-bed **granulation** method.

38. Fine **granules** of claim 28, wherein the enteric coating **layer** comprises an aqueous enteric polymer agent.

39. Fine **granules** of claim 38, wherein the aqueous enteric polymer

agent is a methacrylate copolymer.

40. Fine **granules** of claim 28, wherien the sustained-release agent is a methacrylate copolymer.

41. Fine **granules** of claim 28, wherein the sustained-release agent is in an amount of 5 to 15 weight % relative to 100. . .
42. Fine **granules** of claim 28, wherein the enteric coating **layer** is in an amount of 50 to 70 weight % relative to 100 weight % of the fine **granules**.

43. A tablet, **granule**, fine **granule**, capsule, effervescent or suspension preparation which comprises the fine **granules** of claim 28.

45. Fine **granules** of claim 38, wherein the sustained-release agent is in an amount of 5 to 30% relative to 100 weight %. . .

L15 ANSWER 48 OF 58 USPATFULL on STN
Full Text
PI US 6228400 B1 20010508
CLM What is claimed is:
1. An orally administered pharmaceutical **granule** comprising: an inert core comprising at least one compound and/or mixture selected from the group consisting of starch, a mixture. . . said inert core, wherein said drug emulsion comprises an effective amount of a free base omeprazole or a free base **lansoprazole**, a non-ionic surfactant, a basic amino acid, and water; a protective coating deposited on said drug emulsion, wherein said protective. . .
2. The orally administered pharmaceutical **granule** according to claim 1, wherein said drug emulsion contains 30-60 wt % of water, 1-10 wt % of the non-ionic. . .
3. The orally administered pharmaceutical **granule** according to claim 1, wherein said basic amino acid is selected from the group consisting of arginine, lysine, histidine, and. . .
4. The orally administered pharmaceutical **granule** according to claim 1, wherein said non-ionic surfactant is polyoxypropylene-polyoxyethylene copolymers or polysorbates.

5. The orally administered pharmaceutical **granule** according to claim 1, wherein said polymer and said plasticizer in said enteric **layer** are at a weight ratio of no less than 10:1.

6. The orally administered pharmaceutical **granule** according to claim 1, wherein said **granule** is further encapsulated.

7. The orally administered pharmaceutical **granule** according to claim 1, wherein said **granule** is compressed into tablet by mixing with at least an excipient which is selected from the group consisting of lactose,. . .
8. A process of making an orally administered pharmaceutical **granule** according to claim 1 comprising: obtaining an inert core; coating the inert core with a drug emulsion which comprises a free base omeprazole or a free base **lansoprazole**, a non-ionic surfactant, arginine, and water by spraying said drug emulsion onto said inert core; coating the drug emulsion with. . .
. . . and gastritis comprising orally administering to a host in need of such treatment a therapeutically effective amount of a pharmaceutical **granule** comprising: an inert core consisting essentially of at least one compound and/or mixture selected from the group consisting of starch,. . . said inert core, wherein said drug emulsion comprises an effective amount of a free base omeprazole or a free base **lansoprazole**, a non-ionic surfactant, a basic amino acid, and water; a protective coating deposited on said drug emulsion, wherein said protective. . .
10. An orally administered pharmaceutical **granule** comprising: an inert core comprising at least one compound and/or mixture selected from the group consisting of starch, a mixture. . . said inert core, wherein said drug emulsion comprises an effective amount of a free base omeprazole or a free base **lansoprazole**, a non-ionic surfactant, and water, wherein said drug emulsion does not contain an alkaline salt or compound; a protective coating. . .
11. The orally administered pharmaceutical **granule** according to claim

10, wherein said non-ionic surfactant is polyoxypropylene-polyoxyethylene copolymers or polysorbates.

12. The orally administered pharmaceutical **granule** according to claim 10, wherein said excipient is polyethylene glycol 6000 having a molecular weight between 7000 and 9000.

13. The orally administered pharmaceutical **granule** according to claim 10, wherein said polymer and said plasticizer in said enteric **layer** are at a weight ratio of no less than 10:1.

14. The orally administered pharmaceutical **granule** according to claim 10, wherein said protective coating further comprises a basic amino acid selected from the group consisting of. . .
15. The orally administered pharmaceutical **granule** according to claim 11, wherein said protective coating comprises one or more sublayers.

16. The orally administered pharmaceutical **granule** according to claim 15, wherein at least one of the sublayers contains a basic amino acid selected from the group. . .
17. The orally administered pharmaceutical **granule** according to claim 15, wherein none of the sublayers of the protective coating contains an alkaline salt or compound.

18. The orally administered pharmaceutical **granule** according to claim 10, wherein said **granule** is further encapsulated.

19. The orally administered pharmaceutical **granule** according to claim 10, wherein said **granule** is compressed into tablet by mixing with at least one said excipient which is selected from the group consisting of. . .
20. A process of making an orally administered pharmaceutical **granule** according to claim 10 comprising: obtaining an inert core; coating the inert core with a drug emulsion which comprises a free base omeprazole or a free base **lansoprazole**, a non-ionic surfactant, arginine, and water by spraying said drug emulsion onto said inert core; coating the drug emulsion with. . .
. . . and gastritis comprising orally administering to a host in need of such treatment a therapeutically effective amount of a pharmaceutical **granule** comprising: an inert core consisting essentially of at least one compound and/or mixture selected from the group consisting of starch,. . . said inert core, wherein said drug emulsion comprises an effective amount of a free base omeprazole or a free base **lansoprazole**, a non-ionic surfactant, and water, wherein said drug emulsion does not contain an alkaline salt or compound; a protective coating. . .
22. An orally administered pharmaceutical **granule** comprising: an inert core selected from the groups of compounds and/or mixtures consisting essentially of starch, a mixture of sugar. . . on said inert core, wherein said drug emulsion comprises an effective amount of a freebase omeprazole or a free base **lansoprazole**, a non-ionic surfactant, and water, wherein said drug emulsion does not contain an alkaline salt or compound; a first protective. . .
23. An orally administered pharmaceutical **granule** according to claim 22, wherein said second protective coating further comprises a basic amino acid which is selected from the. . .

L15 ANSWER 51 OF 58 USPATFULL on STN
Full Text
PI US 5824339 19981020
CLM What is claimed is:
1. An effervescent composition which comprises (a) a core-shell powder which comprises a fine **granular** core having a specific volume not exceeding about 5 ml/g coated with a **layer** comprising a water-soluble polymer and an effective amount of an acid-sensitive physiologically active substance and an enteric coating **layer**, wherein the average particle diameters of the core-shell powder do not exceed about 300 μm; (b) an effervescing component; and. . .
2. The effervescent composition as claimed in claim 1, wherein said fine **granular** core is physiologically inactive.

3. The effervescent composition as claimed in claim 1, wherein said fine

granular core is spherical.

7. The effervescent composition as claimed in claim 6, wherein said benzimidazole derivative is **lansoprazole**.

8. The effervescent composition as claimed in claim 1, wherein the proportion of said enteric coating **layer** is about 35 to about 50% by weight of the core-shell powder.

. . . The effervescent composition as claimed in claim 1, which comprises (a) a core-shell powder which comprises a physiologically inactive fine **granular** core coated with a **layer** comprising a water-soluble cellulose derivative and an effective amount of **lansoprazole** and an enteric coating **layer**; (b) an effervescing component selected from alkali metal carbonates; and (c) an auxiliary effervescing agent selected from edible hydroxy-carboxylic acids;. . . .

13. A method of producing an effervescing composition which comprises mixing (a) a core-shell powder which comprises a fine **granular** core having specific volume not exceeding about 5 ml/g coated with a **layer** comprising a water-soluble polymer and an effective amount of acid-sensitive physiologically active substance and an enteric-coating **layer**, wherein the average particle diameters of the core-shell powder do not exceed about 300 μm; with (b) an effervescing component;. .

.

. . . suspension of an acid-sensitive physiologically active substance for oral administration which comprises (a) a core-shell powder which comprises a fine **granular** core having a specific volume not exceeding 5 ml/g coated with a **layer** comprising a water-soluble polymer and an effective amount of acid-sensitive physiologically active substance and an enteric-coating **layer**, wherein the average particle diameters of the core-shell powder to not exceeding about 300 μm; (b) an effervescing component; and. . .

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	129.90	130.11

STN INTERNATIONAL LOGOFF AT 19:12:06 ON 02 MAR 2008